WO2022124298A1 - 多能性幹細胞集団を製造する製造方法 - Google Patents
多能性幹細胞集団を製造する製造方法 Download PDFInfo
- Publication number
- WO2022124298A1 WO2022124298A1 PCT/JP2021/044881 JP2021044881W WO2022124298A1 WO 2022124298 A1 WO2022124298 A1 WO 2022124298A1 JP 2021044881 W JP2021044881 W JP 2021044881W WO 2022124298 A1 WO2022124298 A1 WO 2022124298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture
- cells
- pluripotent stem
- less
- cell
- Prior art date
Links
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 156
- 238000004519 manufacturing process Methods 0.000 title claims description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 103
- 238000004114 suspension culture Methods 0.000 claims abstract description 74
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000007788 liquid Substances 0.000 claims abstract description 45
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 claims abstract description 9
- 101000663006 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 345
- 238000000034 method Methods 0.000 claims description 92
- 238000012258 culturing Methods 0.000 claims description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 10
- 239000011669 selenium Substances 0.000 claims description 10
- 229910052711 selenium Inorganic materials 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 9
- 238000004115 adherent culture Methods 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 239000011435 rock Substances 0.000 claims description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 7
- 239000002211 L-ascorbic acid Substances 0.000 claims description 7
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 7
- 102000004338 Transferrin Human genes 0.000 claims description 7
- 108090000901 Transferrin Proteins 0.000 claims description 7
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 7
- 239000012581 transferrin Substances 0.000 claims description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 abstract description 65
- 230000001070 adhesive effect Effects 0.000 abstract description 65
- 230000030833 cell death Effects 0.000 abstract description 7
- 239000000725 suspension Substances 0.000 abstract description 3
- 239000002609 medium Substances 0.000 description 149
- 239000000126 substance Substances 0.000 description 27
- -1 Go6976 Chemical compound 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 19
- 239000002771 cell marker Substances 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 102100024923 Protein kinase C beta type Human genes 0.000 description 14
- 230000022534 cell killing Effects 0.000 description 14
- 238000012136 culture method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 229940091258 selenium supplement Drugs 0.000 description 9
- ZGSXEXBYLJIOGF-ALFLXDJESA-N IWR-1-endo Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2[C@H](C=C3)C[C@H]3[C@@H]2C1=O ZGSXEXBYLJIOGF-ALFLXDJESA-N 0.000 description 8
- 108010044467 Isoenzymes Proteins 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 108010076089 accutase Proteins 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 235000011649 selenium Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 238000007667 floating Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000001267 GSK3 Human genes 0.000 description 6
- 108060006662 GSK3 Proteins 0.000 description 6
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 6
- 108090000315 Protein Kinase C Proteins 0.000 description 6
- 102000003923 Protein Kinase C Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000004039 endoderm cell Anatomy 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- ZCBUQCWBWNUWSU-SFHVURJKSA-N ruboxistaurin Chemical compound O=C1NC(=O)C2=C1C(C1=CC=CC=C11)=CN1CCO[C@H](CN(C)C)CCN1C3=CC=CC=C3C2=C1 ZCBUQCWBWNUWSU-SFHVURJKSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 6
- QMGUOJYZJKLOLH-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O QMGUOJYZJKLOLH-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 210000001705 ectoderm cell Anatomy 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 210000001704 mesoblast Anatomy 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 210000001635 urinary tract Anatomy 0.000 description 5
- JSQPAEVPPSCQMV-UHFFFAOYSA-N 2-[4-(2-methylsulfonylphenyl)piperazin-1-yl]-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one Chemical compound CS(=O)(=O)C1=CC=CC=C1N1CCN(C=2NC=3CCSCC=3C(=O)N=2)CC1 JSQPAEVPPSCQMV-UHFFFAOYSA-N 0.000 description 4
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 4
- LLJJDLHGZUOMQP-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]-5-methoxy-3-indolyl]-4-(1H-indol-3-yl)pyrrole-2,5-dione Chemical compound C1=CC=C2C(C3=C(C(NC3=O)=O)C3=CN(CCCN(C)C)C4=CC=C(C=C43)OC)=CNC2=C1 LLJJDLHGZUOMQP-UHFFFAOYSA-N 0.000 description 4
- 239000012824 ERK inhibitor Substances 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000013028 medium composition Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- RNUXIZKXJOGYQP-UHFFFAOYSA-N 2-[3-[[4-(4-methoxyphenyl)-5-pyridin-4-yl-1,2,4-triazol-3-yl]sulfanyl]propyl]benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CN=CC=2)=NN=C1SCCCN(C1=O)C(=O)C2=C3C1=CC=CC3=CC=C2 RNUXIZKXJOGYQP-UHFFFAOYSA-N 0.000 description 3
- HSPRASOZRZDELU-LMOVPXPDSA-N 3-[(8s)-8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione;hydrochloride Chemical compound Cl.C12=CC=CC=C2N2CC[C@H](CN(C)C)CC2=C1C1=C(C=2C3=CC=CC=C3N(C)C=2)C(=O)NC1=O HSPRASOZRZDELU-LMOVPXPDSA-N 0.000 description 3
- HIWVLHPKZNBSBE-OUKQBFOZSA-N 4-[5-[(e)-2-[4-(2-chlorophenyl)-5-(5-methylsulfonylpyridin-2-yl)-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]benzonitrile Chemical compound N1=CC(S(=O)(=O)C)=CC=C1C(N1C=2C(=CC=CC=2)Cl)=NN=C1\C=C\C1=NN=C(C=2C=CC(=CC=2)C#N)O1 HIWVLHPKZNBSBE-OUKQBFOZSA-N 0.000 description 3
- 229920001342 Bakelite® Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 3
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101150037203 Sox2 gene Proteins 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229950002189 enzastaurin Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100030634 Homeobox protein OTX2 Human genes 0.000 description 2
- 101000584400 Homo sapiens Homeobox protein OTX2 Proteins 0.000 description 2
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 2
- 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 2
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 2
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 101150012532 NANOG gene Proteins 0.000 description 2
- 101150025224 OCT3 gene Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 101710129670 Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 description 2
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 description 2
- 108010024526 Protein Kinase C beta Proteins 0.000 description 2
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 2
- 102100037314 Protein kinase C gamma type Human genes 0.000 description 2
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108010017601 Tankyrases Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004637 bakelite Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 210000001368 germline stem cell Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 229950005814 sotrastaurin Drugs 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- GSDZHIVWGRCICQ-UHFFFAOYSA-N 3-(1-methylindol-3-yl)pyrrole-2,5-dione;hydrochloride Chemical compound Cl.C12=CC=CC=C2N(C)C=C1C1=CC(=O)NC1=O GSDZHIVWGRCICQ-UHFFFAOYSA-N 0.000 description 1
- MPXAEYSGFKRDQM-UHFFFAOYSA-N 3-[4-(2-hydroxypropan-2-yl)phenyl]-6-methyl-2h-pyrrolo[1,2-a]pyrazin-1-one Chemical compound CC1=CC=C(C(N2)=O)N1C=C2C1=CC=C(C(C)(C)O)C=C1 MPXAEYSGFKRDQM-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QGNQEODJYRGEJX-UHFFFAOYSA-N 4h-isoquinoline-1,3-dione Chemical compound C1=CC=C2C(=O)NC(=O)CC2=C1 QGNQEODJYRGEJX-UHFFFAOYSA-N 0.000 description 1
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229940125928 ERK kinase inhibitor Drugs 0.000 description 1
- 102100030751 Eomesodermin homolog Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 102100021084 Forkhead box protein C1 Human genes 0.000 description 1
- 102100020856 Forkhead box protein F1 Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 102100023855 Heart- and neural crest derivatives-expressed protein 1 Human genes 0.000 description 1
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102100030941 Homeobox even-skipped homolog protein 1 Human genes 0.000 description 1
- 102100024208 Homeobox protein MIXL1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 description 1
- 101000818310 Homo sapiens Forkhead box protein C1 Proteins 0.000 description 1
- 101000931494 Homo sapiens Forkhead box protein F1 Proteins 0.000 description 1
- 101000905239 Homo sapiens Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 1
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 1
- 101000938552 Homo sapiens Homeobox even-skipped homolog protein 1 Proteins 0.000 description 1
- 101001052462 Homo sapiens Homeobox protein MIXL1 Proteins 0.000 description 1
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 1
- 101001053430 Homo sapiens Iroquois-class homeodomain protein IRX-3 Proteins 0.000 description 1
- 101100510266 Homo sapiens KLF4 gene Proteins 0.000 description 1
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 description 1
- 101000800571 Homo sapiens T-box transcription factor T Proteins 0.000 description 1
- 101000625859 Homo sapiens T-box transcription factor TBX6 Proteins 0.000 description 1
- 101000655403 Homo sapiens Transcription factor CP2-like protein 1 Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 1
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102100024374 Iroquois-class homeodomain protein IRX-3 Human genes 0.000 description 1
- 101150070299 KLF4 gene Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100478674 Mus musculus Stk3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 101150085710 OCT4 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101710129674 Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100033130 T-box transcription factor T Human genes 0.000 description 1
- 102100024751 T-box transcription factor TBX6 Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108010033711 Telomeric Repeat Binding Protein 1 Proteins 0.000 description 1
- 102100036497 Telomeric repeat-binding factor 1 Human genes 0.000 description 1
- 102100032866 Transcription factor CP2-like protein 1 Human genes 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 1
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000007562 laser obscuration time method Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- SAWVGDJBSPLRRB-UHFFFAOYSA-N methanesulfonic acid;3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate Chemical compound CS(O)(=O)=O.C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCSC(N)=N)C=2)C(=O)NC1=O SAWVGDJBSPLRRB-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical class OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000000276 neural tube Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108010061269 protein kinase D Proteins 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 150000003342 selenium Chemical class 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/724—Glycosyltransferases (EC 2.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
Definitions
- the present invention relates to a method for producing a pluripotent stem cell population, which is a culture target of pluripotent stem cells and undergoes adhesive culture to suspension culture.
- Pluripotent stem cells such as ES cells and iPS cells have the ability to proliferate indefinitely and differentiate into various somatic cells.
- the practical application of a treatment method for transplanting somatic cells induced to differentiate from pluripotent stem cells has the potential to radically change the treatment method for intractable diseases and lifestyle-related diseases.
- a technique for inducing differentiation of pluripotent stem cells into a wide variety of somatic cells such as nerve cells, cardiomyocytes, blood cells, and retinal cells at the in vitro level has already been developed.
- pluripotent stem cells still has problems for practical use, and one of the problems is the productivity of pluripotent stem cells themselves. For example, it is said that about 2 ⁇ 10 11 cells are required for liver regeneration.
- the method for culturing pluripotent stem cells is roughly classified into adhesion culture in which cells are adhered to a flat culture substrate (plate) and cultured, and suspension culture in which cells are suspended and cultured in a liquid medium.
- a culture substrate (plate) of 106 cm 2 or more is required, which is equivalent to about 20,000 cells in a general 10 cm dish.
- Non-Patent Document 1 discloses a method of suspending and culturing pluripotent stem cells while stirring a liquid medium using a spinner flask as a cell culture container for suspension culture.
- Patent Document 1 discloses a method for efficiently forming cell aggregates for suspension culture by dispensing pluripotent stem cells dispersed in single cells into a container having a concave curved surface at the center of the bottom of the well. ing.
- Patent Document 2 discloses that pluripotent stem cells are suspended and cultured in the presence of a Wnt signal inhibitor.
- Patent Document 3 discloses a medium for culturing stem cells, which contains a PKC (protein kinase C) inhibitor and the like, and does not contain a growth factor or has a low concentration.
- Patent Document 4 discloses a method for culturing human pluripotent stem cells, in which the undifferentiated cells are maintained with a higher probability by adding a PKC inhibitor to the medium and culturing the cells.
- Patent Document 5 describes a method of culturing prime-type pluripotent stem cells while maintaining an undifferentiated state.
- the pluripotent stem cells are cultured in a medium containing a histone deacetylase inhibitor or the like, and then histone deacetylase is formed.
- a method of culturing in a medium containing a MAPK / ERK kinase inhibitor, a PKC inhibitor, a Wnt signal inhibitor and a leukemia inhibitor without containing an enzyme inhibitor is disclosed.
- an object of the present invention is to provide a method for producing pluripotent stem cells, which can suppress cell death when pluripotent stem cells are transferred from adherent culture to suspension culture and can be efficiently cultured. ..
- the present inventors have conducted the above-mentioned adhesion culture as a PKC ⁇ inhibitor in a method for producing a pluripotent stem cell population by shifting pluripotent stem cells from adhesion culture to suspension culture. We have found that it is possible to prevent the death of pluripotent stem cells after the transition to suspension culture by performing in the presence of the TNKS inhibitor, and completed the present invention.
- the present invention includes the following.
- Pluripotent stem cell population including a step of adhering and culturing pluripotent stem cells in a liquid medium containing a PKC ⁇ inhibitor and a TNKS inhibitor, and a step of suspending and culturing pluripotent stem cells after adherent culture. Manufacturing method.
- liquid medium contains at least one selected from the group consisting of L-ascorbic acid, insulin, transferrin, selenium and sodium hydrogen carbonate.
- step of suspension culture includes a step of forming a cell agglomerate.
- step of suspension culture includes a step of collecting cell aggregates.
- the ratio of cells positive for OCT4 is 90% or more
- the ratio of cells positive for SOX2 is 90% or more
- the ratio of cells positive for NANOG is 90% or more.
- pluripotent stem cells are ES cells and / or induced pluripotent stem cells.
- a pluripotent stem cell killing inhibitor for adhesive culture which comprises a PKC ⁇ inhibitor and a TNKS inhibitor.
- the PKC ⁇ inhibitor includes Go6983, GF109203X, LY-333531, Enzastaurin, Sotrastaurin, Ro-31-8220-mesylate, Ro-32-0432-hydrochloride, Go6976, Luteolin, Midoritain, Midoritain, Midorin The method according to (1). The method according to (1). Inhibitor.
- the TNKS inhibitor is at least one selected from the group consisting of IWR-1-endo, XAV939, G007-LK, G244-LM and WIKI4.
- the method according to (1) and the adhesion according to (14). Pluripotent stem cell killing inhibitor for culture.
- composition kit for pluripotent stem fine adhesion culture which comprises a liquid medium composition containing no LIF.
- composition kit for pluripotent stem fine adhesion culture which comprises a liquid medium composition containing no GSK3 inhibitor.
- composition kit for pluripotent stem fine adhesion culture which comprises a liquid medium composition containing no GSK3 inhibitor and MEK / ERK inhibitor.
- the PKC ⁇ inhibitor is a compound having the following structural formula [Formula I].
- the method according to (1) and the pluripotent stem cell killing inhibitor for adhesive culture according to (14). A compound represented by or a salt thereof.
- R 1 is a hydrogen atom or an alkoxy group having 1 to 3 carbon atoms (preferably a methoxy group)
- R 2 is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms (preferably a methyl group), or -N (preferably a methyl group).
- RA An alkyl group having 1 to 3 carbon atoms substituted with 2 (preferably ⁇ (CH 2 ) 3 -N (CH 3 ) 2 ).
- RA is independently an ethyl group or a methyl group (preferably a methyl group).
- # refers to the bond to the bond position of R 2
- ## refers to the bond to the bond position of RB.
- the configuration of the asymmetric carbon contained in the divalent group is not particularly limited, but is preferable.
- RC is an alkyl group having 1 to 3 carbon atoms substituted with ⁇ N ( RD ) 2 (preferably ⁇ (CH 2 ) ⁇ N (CH 3 ) 2 ).
- RD is independently an ethyl group or a methyl group (preferably a methyl group).
- Examples of the salt of the compound represented by the formula I include hydrochlorides and sulfates.
- the step of suspension-culturing the pluripotent stem cells is characterized in that the pluripotent stem cells after the adhesion culture are inoculated into a liquid medium containing no PKC ⁇ inhibitor and / or a TNKS inhibitor (1).
- pluripotent stem cells when transferred from adherent culture to suspension culture, it is possible to prevent the death of pluripotent stem cells and efficiently produce a pluripotent stem cell population.
- Example 3 is a characteristic diagram showing the expression levels of the OCT4 gene, the NANOG gene, and the SOX2 gene when pluripotent stem cells were adherently cultured by the methods shown in Example 1 and Comparative Example 1.
- pluripotent stem cell population 1-1.
- Outline In the method for producing a pluripotent stem cell population according to the present invention, first, pluripotent stem cells are adherently cultured in a liquid medium containing a protein kinase C ⁇ (PKC ⁇ ) inhibitor and a tankylase (TNKS) inhibitor, and then pluripotent stem cells are adherently cultured. , To shift to suspension culture to produce pluripotent stem cell populations. According to the method for producing a pluripotent stem cell population according to the present invention, the death of pluripotent stem cells that occurs during the transition from adherent culture to suspension culture can be prevented, and the pluripotent stem cell population can be efficiently produced.
- PLC ⁇ protein kinase C ⁇
- TNKS tankylase
- pluripotency capable of differentiating into all kinds of cells constituting a living body, and under appropriate conditions.
- pluripotency means the ability to differentiate into the germ layers that make up an individual (in vertebrates, the ectoderm, mesoderm and endoderm trigerm).
- Such cells include, for example, embryonic stem cells (ES cells: embryonic stem cells), embryonic stem cells (EG cells: embryonic stem cells), germline stem cells (GS cells: germline stem cells), and induced pluripotency. Examples thereof include stem cells (iPS cells: induced pluripotent stem cells).
- ES cells are pluripotent stem cells prepared from early embryos.
- EG cells are pluripotent stem cells prepared from fetal primordial germ cells (Shamblott MJ et al., 1998, Proc. Natl. Acad. Sci. USA., 95: 13726-13731. ).
- a "GS cell” is a pluripotent stem cell prepared from the cell testis (Conrad S., 2008, Nature, 456: 344-349).
- the "iPS cell” refers to a reprogrammed pluripotent stem cell that puts a somatic cell into an undifferentiated state by introducing a gene encoding a small number of reprogramming factors into the differentiated somatic cell.
- the pluripotent stem cells in the present specification may be cells derived from multicellular organisms. It is preferably an animal-derived cell, more preferably a mammalian-derived cell. Examples thereof include rodents such as mice, rats, hamsters and guinea pigs, livestock or pets such as dogs, cats, rabbits, cows, horses, sheep and goats, and primates such as humans, red-tailed monkeys, gorillas and chimpanzees. .. Particularly preferred are human-derived cells.
- Pluripotent stem cells used herein include naive pluripotent stem cells and prime pluripotent stem cells.
- Naive pluripotent stem cells are in a state close to pluripotency found in the inner cell mass before implantation, and prime pluripotent stem cells are in a state close to pluripotency found in epiblast after implantation.
- Prime-type pluripotent stem cells contribute less frequently to individual development than naive-type pluripotent stem cells, have only one transcriptional activity on the X chromosome, and have high levels of transcriptional repressive histone modification. There is a feature such as being.
- the marker gene in prime-type pluripotent stem cells is OTX2, and the marker gene in naive-type pluripotent stem cells is REX1 and KLF family. Furthermore, the colonization of prime-type pluripotent stem cells is flat, and the colonization of naive-type pluripotent stem cells is dome-shaped. As the pluripotent stem cells used in the present specification, it is particularly preferable to use prime-type pluripotent stem cells.
- pluripotent stem cells used in the present specification commercially available cells or cells that have been distributed may be used, or newly prepared cells may be used. Although not limited, iPS cells or ES cells are preferable as the pluripotent stem cells when used in each invention of the present specification.
- iPS cells used in the present specification are commercially available products, for example, 253G1 strain, 253G4 strain, 201B6 strain, 201B7 strain, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, 648A1 strain, HiPS-RIKEN.
- iPS cells used in the present specification are clinical strains, for example, QHJI01s01 strain, QHJI01s04 strain, QHJI14s03 strain, QHJI14s04 strain, Ff-l14s03 strain, Ff-l14s04 strain, YZWI strain and the like are used. can do.
- the combination of genes of the reprogramming factor to be introduced is not limited, but is, for example, OCT3 / 4 gene, KLF4 gene, SOX2 gene and c. -Myc gene combination (YuJ, et al. 2007, Science, 318: 1917-20.), OCT3 / 4 gene, SOX2 gene, LIN28 gene and NANOG gene combination (Takahashi K, et al. 2007, Cell, 131: 861-72.) Can be used.
- the form of introduction of these genes into cells is not particularly limited, but for example, gene transfer using a plasmid, introduction of synthetic RNA, or introduction as a protein may be used.
- iPS cells prepared by a method using microRNA, RNA, a small molecule compound or the like may be used. Needless to say, newly prepared clinical grade iPS cells may be used.
- KhES-1 strain, KhES-2 strain, KhES-3 strain, KhES-4 strain, KhES-5 strain, SEES1 strain, SEES2 strain are not limited.
- SEES3 strain, SES-4 strain, SEES-5 strain, SES-6 strain, SES-7 strain, HUES8 strain, CyT49 strain, H1 strain, H9 strain, HS-181 strain and the like can be used.
- cell aggregate is a mass of cells formed by cell aggregation in suspension culture, and is also referred to as spheroid.
- Cell aggregates are usually substantially spherical.
- the cells constituting the cell aggregate are not particularly limited as long as they are one or more types of the cells.
- cell aggregates composed of pluripotent stem cells such as human pluripotent stem cells or human embryonic stem cells express pluripotent stem cell markers and / or are positive for pluripotent stem cell markers. Includes presenting cells.
- the cell mass may be formed via a microcarrier.
- Pluripotent stem cell markers are genetic markers that are specifically or overexpressed in pluripotent stem cells, such as Alkaline phosphatase, NANOG, OCT4, SOX2, TRA-1-60, c-Myc, KLF4, LIN28. , SSEA-4, SSEA-1, and the like can be exemplified.
- Pluripotent stem cell markers can be detected by any detection method in the art.
- Methods for detecting cell markers include, but are not limited to, flow cytometry, for example.
- a fluorescently labeled antibody is used as a detection reagent in flow cytometry, when a cell that emits stronger fluorescence than a negative control (isotype control or FMO control) is detected, the cell is "positive" for the marker. Is determined.
- the percentage of cells that are positive for a fluorescently labeled antibody analyzed by flow cytometry is sometimes referred to as the "positive rate.”
- the fluorescently labeled antibody any antibody known in the art can be used, and for example, an antibody labeled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), or the like. However, it is not limited to these.
- the positive rate of the pluripotent stem cell marker is preferably 80% or more, more preferably 90% or more, more preferably 91% or more, and more preferably 92. % Or more, more preferably 93% or more, more preferably 94% or more, more preferably 95% or more, more preferably 96% or more, more preferably 97% or more, more preferably 98% or more, more preferably 99%. As mentioned above, it is more preferably 100% or less.
- Cell clusters that express pluripotent stem cell markers and / or have a percentage of cells that are positive for pluripotent stem cell markers within the above range are highly undifferentiated and more homogeneous cell populations.
- Adhesive culture is one of the cell culture methods, and means that cells are adhered to an external matrix such as a culture vessel and typically grown in a single layer.
- the external matrix is not particularly limited, and for example, Laminin, Vitronectin, Gelatin, Collagen, E-Cadherin chimeric antibody and the like can be used.
- As a cell culture method there is a suspension culture method as another culture method different from the adhesive culture.
- Floating culture refers to growing cells in a floating state in a medium. As used herein, the term “floating state” refers to a non-adherent state in which cells are not fixed to a culture vessel or the like in a culture solution.
- the cells are adhered to the microcarriers, but the cell mass containing the microcarriers is adhered to the culture vessel. It floats without any activity and can be regarded as a floating culture.
- the "suspension culture method” is a method for suspending and culturing cells, and the cells in this method generally exist as a cell mass aggregated in a culture medium.
- the above-mentioned cells can usually be cultured not only in adhesive culture but also in suspension culture.
- the term "medium” refers to a liquid or solid substance prepared for culturing cells. As a general rule, it contains the minimum necessary components that are essential for cell proliferation and / or maintenance. Unless otherwise specified, the medium of the present specification corresponds to a liquid medium for animal cells used for culturing animal-derived cells.
- basal medium refers to the medium that forms the basis of various animal cell media. It can be cultured alone, or it can be prepared into a medium specific to various cells according to the purpose by adding various culture additives.
- Basal medium used in the present specification, BME medium, BGJb medium, CMRL1066 medium, Glasgow MEM medium, Applied MEM Zinc Option medium, IMDM medium (Iscover'S Modified Dulvecco'S Medium 99), Medium 1 , ⁇ MEM medium, DMEM medium (Dulvecco'S Modified Eagle'S Medium), ham F10 medium, ham F12 medium, RPMI 1640 medium, Fisher'S medium, and a mixed medium thereof (for example, DMEM / F12 medium (Dulvecco'S)).
- the medium is not particularly limited.
- the weight ratio of the DMEM medium and the ham F12 medium is preferably in the range of 60/40 or more and 40/60 or less, for example, 58/42, 55/45, 52/48, 50/50, 48. Medium mixed at / 52, 45/55, 42/58, etc. is used.
- the medium used for culturing human iPS cells and human ES cells can also be preferably used.
- the medium used in the present invention is preferably a serum-free medium, that is, a serum-free medium.
- the "culture additive” is a substance other than serum added to the medium for the purpose of culture.
- culture additives include, but are not limited to, L-ascorbic acid, insulin, transferase, selenium, sodium hydrogen carbonate, growth factors, fatty acids or lipids, amino acids (eg, non-essential amino acids), vitamins, cytokines, antioxidants. Agents, 2-mercaptoethanol, pyruvate, buffers, inorganic salts, antibiotics and the like.
- Insulin, transferrin, and cytokines may be of natural origin isolated from animal (preferably human, mouse, rat, bovine, horse, goat, etc.) tissues or sera, or genetically engineered. It may be a recombinant protein.
- the growth factors are not limited, but are, for example, FGF2 (Basic fibroblast growth factor-2), TGF- ⁇ 1 (Transforming growth factor- ⁇ 1), Activin A, IGF-1, MCP-1, IL-6. , PAI, PEDF, IGFBP-2, LIF, and IGFBP-7 can be used.
- FGF2 Basic fibroblast growth factor-2
- TGF- ⁇ 1 Transforming growth factor- ⁇ 1
- Activin A IGF-1
- MCP-1 IL-6
- PAI PAI
- PEDF IGFBP-2
- LIF low-IL-6
- IGFBP-7 antibiotics
- Particularly preferred growth factors for the culture medium culture additive used in the present invention are FGF2 and / or TGF- ⁇ 1.
- the medium contains a ROCK inhibitor.
- the ROCK inhibitor include Y-27632.
- the concentration of the ROCK inhibitor in the medium can be a lower limit of 1 ⁇ M, 2 ⁇ M, 3 ⁇ M, 5 ⁇ M, 7 ⁇ M, or 10 ⁇ M, and an upper limit of 50 ⁇ M, 40 ⁇ M, 30 ⁇ M, 20 ⁇ M, or 10 ⁇ M.
- the medium preferably has a composition that does not contain LIF, especially when prime-type pluripotent stem cells are to be cultured. Furthermore, when prime-type pluripotent stem cells are to be cultured, it is preferable to have a medium composition that does not contain either one of the GSK3 inhibitor and the MEK / ERK inhibitor, preferably both. If the medium does not contain these LIF, GSK3 inhibitor, and MEK / ERK inhibitor, prime-type pluripotent stem cells can be cultured without being naive and in an undifferentiated state.
- the medium used in the present invention can contain one or more of the above-mentioned culture additives.
- the medium to which the culture additive is added is not limited, but the basal medium is generally used.
- Culture additives can be added to the medium in the form of solutions, derivatives, salts, mixed reagents and the like.
- L-ascorbic acid may be added to the medium in the form of a derivative such as magnesium 2-ascorbic acid 2-phosphate
- selenium may be added to the medium in the form of a selenium salt (sodium selenite, etc.). May be good.
- Insulin, transferrin, and selenium can also be added to the medium in the form of an ITS reagent (insulin-transferrin-selenium). It is also possible to use a commercially available medium supplemented with at least one selected from L-ascorbic acid, insulin, transferrin, selenium and sodium hydrogen carbonate.
- CHO-S-SFM II Life Technologies Japan Co., Ltd.
- Hybridoma-SFM Life Technologies Japan Co., Ltd.
- eRDF Dry Powered Media Life Technologies Japan Co., Ltd.
- UltraCULTURE UltraCULTURE
- the most preferable medium used in the present invention is a serum-free medium containing L-ascorbic acid, insulin, transferrin, selenium and sodium hydrogen carbonate, and at least one growth factor.
- a serum-free medium containing L-ascorbic acid, insulin, transferrin, selenium and sodium hydrogen carbonate, and at least one growth factor.
- Particularly preferred is DMEM / F12 medium containing L-ascorbic acid, insulin, transferrin, selenium and sodium bicarbonate, and at least one growth factor (preferably FGF2 and TGF- ⁇ 1) and serum-free.
- protein kinase C ⁇ (PKC ⁇ ) inhibitor means a substance that inhibits or suppresses the activity of PKC ⁇ .
- PKC ⁇ protein kinase C ⁇
- Protein kinases have a catalytic region on the C-terminal side and a regulatory region on the N-terminal side.
- the catalytic region is composed of a sequence that recognizes a phosphorylated residue on the substrate protein and a sequence that binds to ATP / Mg 2+ .
- the regulatory region is composed of the C1 domain and the C2 domain.
- PKC includes PKC ⁇ , PKC ⁇ I, PKC ⁇ II and PKC ⁇ as conventional isozymes.
- PKC includes PKC ⁇ , PKC ⁇ , PKC ⁇ and PKC ⁇ as novel isozymes, and PKC ⁇ , PKC ⁇ and PKC ⁇ as atypical isozymes.
- PKC ⁇ means a case where both PKC ⁇ I and PKC ⁇ II are included, or a case where one of PKC ⁇ I and PKC ⁇ II is included.
- PKC ⁇ inhibitor as used herein means a substance that inhibits at least PKC ⁇ I and / or PKC ⁇ II among these conventional, novel and atypical isozymes. That is, the PKC ⁇ inhibitor means a substance that inhibits or suppresses only the activity of PKC ⁇ I, a substance that inhibits or suppresses only the activity of PKC ⁇ II, and a substance that inhibits or suppresses the activity of PKC ⁇ I and PKC ⁇ II.
- the PKC ⁇ inhibitor may be a substance that specifically inhibits or suppresses only the activity of PKC ⁇ , but may be a substance that inhibits or suppresses the activity of other isozymes other than PKC ⁇ I or PKC ⁇ II.
- the PKC ⁇ inhibitor may be a substance that inhibits or suppresses the activity of all the conventional, neoplastic and atypical isozymes described above, including PKC ⁇ I and PKC ⁇ II.
- the PKC ⁇ inhibitor may be a substance that inhibits or suppresses the activities of the conventional isozymes PKC ⁇ and PKC ⁇ in addition to PKC ⁇ I and PKC ⁇ II.
- the PKC ⁇ inhibitor may be a substance that inhibits or suppresses the activities of the new isozymes PKC ⁇ , PKC ⁇ , PKC ⁇ and PKC ⁇ in addition to PKC ⁇ I and PKC ⁇ II.
- the PKC ⁇ inhibitors described above include compounds that act directly or indirectly on PKC ⁇ , antisense nucleic acids for genes encoding PKC ⁇ , RNA interference-inducing nucleic acids (eg, siRNA), dominant negative variants, and theirs. Expression vectors may be mentioned.
- the PKC ⁇ inhibitor can be a compound having the following structural formula [Formula I]. A compound represented by or a salt thereof.
- R 1 is a hydrogen atom or an alkoxy group having 1 to 3 carbon atoms (preferably a methoxy group).
- R 2 is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms (preferably a methyl group), or an alkyl group having 1 to 3 carbon atoms substituted with —N ( RA ) 2 (preferably ⁇ (CH 2 ). ) 3 -N (CH 3 ) 2 ), RA is independently an ethyl group or a methyl group (preferably a methyl group).
- # refers to the bond to the bond position of R 2
- ## refers to the bond to the bond position of RB.
- the configuration of the asymmetric carbon contained in the divalent group is not particularly limited, but is preferable.
- RC is an alkyl group having 1 to 3 carbon atoms substituted with ⁇ N ( RD ) 2 (preferably ⁇ (CH 2 ) ⁇ N (CH 3 ) 2 ).
- RD is independently an ethyl group or a methyl group (preferably a methyl group).
- Examples of the salt of the compound represented by the formula I include hydrochlorides and sulfates.
- PKC ⁇ inhibitor having the above structural formula [Formula I] include Go6983, GF109203X, LY-333531, Enzastaurin, Sotrastaurin, Ro-31-8220-messylate, Ro-32-0432-hydrochloride, Go6976, Rotter. , Midostaurin, Daphnetin, Dequalinium Chloride, Baicalein, Quercetin, Luteolin, Bisindolillmalymide II, Calphostin C, Cellerythrine Chloride can be selected from the group In particular, among the PKC ⁇ inhibitors having the above structural formula, it is preferable to use a compound selected from the group consisting of Go6983, GF109203X and LY-333531.
- LY-333531 ((9S)-[(dimethylamino) methyl] -6,7,10,11-tetrahydro-9H, 18H-5,21: 12,17-dimethenodibenzo [e, k] pyrrolo [3,4- h] [1,4,13] Oxaziazacyclohexadecin-18,20 (19H) -dione, monohydroxychloride) structural formulas are shown below.
- Enzastaurin (3- (1-methylindole-3-yl) -4- [1- [1- (pyridin-2-ylmethyl) piperidine-4-yl] indole-3-yl] pyrrole-2,5-dione)
- the structural formula of is shown below.
- Ro-31-8220-messylate (3- [3- [2,5-dihydro-4- (1-methyl-1H-indole-3-yl) -2,5-dioxo-1H-pyrrole-3-yl]]
- the structural formula of -1H-indole-1-yl] propylcarbamimide thioate ester mesylate) is shown below.
- Ro-32-0432-hydrochloride (3-[(8S) -8-[(dimethylamino) methyl] -6,7,8,9-tetrahydropyrrole [1,2-a] indole-10-yl]-
- the structural formula of 4- (1-methyl-1H-indole-3-yl) -1H-pyrrole-2,5-dione hydrochloride) is shown below.
- tankyrace (TNKS) inhibitor means a substance that inhibits or suppresses the activity of tankyrace.
- Tankyrase (sometimes referred to as tankyrase) belongs to the poly (ADP-ribosyl) -forming enzyme (PARP) family that poly (ADP-ribosyl) the target protein, and tankyrase 1 (tankyrase-1 / PARP-5a).
- PARP-5b tankyrase-2
- tankyrace it is known that the telomere protein TRF1 is poly (ADP-ribosyl) and released from telomere to promote telomere elongation by telomerase.
- TNKS means a case where both tanker lace 1 and tanker lace 2 are included, or a case where one of tanker lace 1 and tanker lace 2 is included.
- TNKS inhibitor as used herein means a substance that inhibits tankyrace 1 and / or tankyrace 2. That is, the TNKS inhibitor includes a substance that inhibits or suppresses only the activity of tankyrace 1, a substance that inhibits or suppresses only the activity of tankirace 2, and a substance that inhibits or suppresses the activity of tankirase 1 and tankirase 2. Meaning.
- TNKS inhibitors include compounds that act directly or indirectly on TNKS, antisense nucleic acids for genes encoding TNKS, RNA interference-inducing nucleic acids (eg, siRNA), dominant negative variants, and their expression vectors. Can be mentioned.
- examples of the TNKS inhibitor include compounds selected from the group consisting of IWR-1-endo, XAV939, G007-LK, G244-LM, MSC2504877 and WIKI4.
- G007-LK (4- [5-[(1E) -2- [4- (2-chlorophenyl) -5- [5- (methylsulfonyl) -2-pyridinyl] -4H-1,2,4-thiazol-
- the structural formula of 3-yl] ethenyl] -1,3,4-oxadiazol-2-yl] -benzonitrile) is shown below.
- G244-LM (3,5,7,8-tetrahydro-2- [4- [2- (methylsulfonyl) phenyl] -1-piperazinyl] -4H-thiopyrano [4,3-d] pyrimidin-4-one)
- the structural formula of is shown below.
- WIKI4 (2- [3-[[4- (4-Methoxyphenyl) -5- (4-pyridinyl) -4H-1,2,4-thiazol-3-yl] thio] propyl] -1H-benzo [de ]
- the structural formula of isoquinoline-1,3 (2H) -dione) is shown below.
- the method for producing a pluripotent stem cell population according to the present invention is to first adherently culture a pluripotent stem cell population and then shift to suspension culture.
- the liquid medium used for adhesive culture is the above 1-2.
- the PKC ⁇ inhibitor and the TNKS inhibitor defined in the above are contained as active ingredients. Therefore, one aspect of the present invention is a pluripotent stem cell killing inhibitor for adhesive culture containing a PKC ⁇ inhibitor and a TNKS inhibitor as active ingredients.
- the PKC ⁇ inhibitor may be one kind or a combination of two or more different kinds.
- the concentration of the PKC ⁇ inhibitor in the composition can be determined to be within a desired range (described later) when added to the medium. can.
- the TNKS inhibitor may be one kind or a combination of two or more different kinds.
- the concentration of the TNKS inhibitor in the composition can be determined to be within a desired range (described later) when added to the medium. can.
- the PKC ⁇ inhibitor and the TNKS inhibitor which are the active ingredients, can be added to the medium in combination with the carrier.
- Carriers include solvents and / or excipients.
- solvent examples include water, buffer (including PBS), physiological saline, organic solvent (DMSO, DMF, xylene, lower alcohol) and the like.
- excipients examples include antibiotics, buffers, thickeners, colorants, stabilizers, surfactants, emulsifiers, preservatives, preservatives, antioxidants and the like.
- the antibiotic is not particularly limited, but for example, penicillin, streptomycin, amphotericin B and the like can be used.
- the buffer include a phosphate buffer solution, a Tris-hydrochloric acid buffer solution, a glycine buffer solution and the like.
- the thickener include gelatin, polysaccharides and the like.
- the colorant include phenol red and the like.
- stabilizer examples include albumin, dextran, methylcellulose, gelatin and the like.
- surfactant examples include cholesterol, alkyl glycosides, alkyl polyglucosides, alkyl monoglyceryl ethers, glucosides, maltosides, neopentyl glycols, polyoxyethylene glycols, thioglucosides, thiomaltosides, peptides, saponins, phospholipids and fatty acids.
- examples include sorbitan ester and fatty acid diethanolamide.
- the emulsifier examples include glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, sucrose fatty acid ester and the like.
- Preservatives include aminoethylsulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, canten, dl-camfur, citric acid, sodium citrate, salicylic acid, sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, sorbic acid.
- Potassium sorbate nitrogen, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, paraoxybenzoic acid
- Examples include methyl, l-menthol, and eucalyptus oil.
- preservative examples include benzoic acid, sodium benzoate, ethanol, sodium edetate, dried sodium sulfite, citric acid, glycerin, salicylic acid, sodium salicylate, dibutylhydroxytoluene, D-sorbitol, sorbic acid, potassium sorbate, and dehydro.
- examples thereof include sodium acetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, propylene glycol, phosphoric acid and the like.
- Antioxidants include citric acid, citric acid derivatives, vitamin C and its derivatives, lycopene, vitamin A, carotenoids, vitamin B and its derivatives, flavonoids, polyphenols, glutathione, selenium, sodium thiosulfate, vitamin E and Examples thereof include ⁇ -lipoic acid and its derivatives, pycnogenol, flavonogenol, superoxide dismutase (SOD), glutathione peroxidase, glutathione-S-transferase, glutathione reductase, catalase, ascorbic acid peroxidase, and mixtures thereof. ..
- the pluripotent stem cell killing inhibitor for adhesive culture may contain one or more growth factors.
- Growth factors include, for example, FGF2 and TGF- ⁇ 1.
- the method for producing a pluripotent stem cell population of the present invention it is possible to suppress the death of pluripotent stem cells when the pluripotent stem cells are cultured by adhesive culture and then the pluripotent stem cells are suspended-cultured.
- Suppressing the death of pluripotent stem cells is synonymous with being able to maintain a high cell number when the pluripotent stem cells are suspended-cultured after adherent culture. That is, the cells were adherently cultured in the presence of a PKC ⁇ inhibitor and a TNKS inhibitor, and then adherently cultured in the absence of the number of cells in suspension culture and one or both of the PKC ⁇ inhibitor and the TNKS inhibitor. After that, when the number of cells in suspension culture under the same conditions is compared, it is higher in the case of adhesive culture in the presence of the PKC ⁇ inhibitor and the TNKS inhibitor.
- the death of cells in suspension culture can be suppressed, so that the pluripotent stem cell population can be efficiently produced by suspension culture. That is, a pluripotent stem cell population consisting of a desired number of cells can be produced in a relatively short period of time. This can significantly reduce the cost of producing a pluripotent stem cell population.
- Culturing step The method of this embodiment includes an adhesive culturing step and a subsequent suspension culturing step. Further, the method of this embodiment may include a recovery step. Hereinafter, each process will be described.
- Adhesion culture step is a step of culturing a cell population before a suspension culture step in order to proliferate cells while maintaining an undifferentiated state.
- an animal cell culture method known in the art can be utilized.
- it may be an adhesive culture in which cells are cultured while being adhered to a culture substrate such as a container or a carrier.
- cell The cells used in this step are cells capable of adhesive culture and capable of cell aggregation in the suspension culture described later.
- animal cells are preferable, and human cells are more preferable.
- the cell type is pluripotent stem cells, and pluripotent stem cells such as iPS cells and ES cells are particularly preferable.
- the pluripotent stem cell used in this step may be a single cell or a cell population consisting of a plurality of cells (pluripotent stem cell population).
- pluripotent stem cell is a pluripotent stem cell population
- the percentage of cells expressing the pluripotent stem cell marker eg, Oct4, SOX2, NANOG
- the pluripotent stem cell marker eg, Oct4, SOX2, NANOG
- (Ratio) is, for example, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 100%. ..
- the culture container used for adhesive culture is not particularly limited, but a container in which the inner surface of the container is not treated to suppress protein adsorption is preferable, and a container capable of coating an external matrix is preferable.
- the shape of the culture vessel is not particularly limited, and examples thereof include a culture vessel having a dish shape, a flask shape, a well shape, a bag shape, a spinner flask shape, and the like.
- a petri dish for cell culture (Sumitomo Bakelite Co., Ltd.) can be used as a culture container.
- the capacity of the culture vessel to be used can be appropriately selected and is not particularly limited, but the lower limit of the area when the bottom surface of the portion containing the medium is viewed in a plan view is 0.32 cm 2 or more, 0.65 cm 2 or more, 1 9.9 cm 2 or more, 3.0 cm 2 or more, 3.5 cm 2 or more, 9.0 cm 2 or more, or 9.6 cm 2 or more, and the upper limit is 1000 cm 2 or less, 500 cm 2 or less, 300 cm 2 or less, 150 cm 2 or less, It is preferably 75 cm 2 or less, 55 cm 2 or less, 25 cm 2 or less, 21 cm 2 or less, 10 cm 2 or less, or 3.5 cm 2 or less.
- the capacity of the culture vessel to be used can be appropriately selected and is not particularly limited, but the lower limit of the volume that can accommodate and culture the medium is 1 mL, 2 mL, 4 mL, 10 mL, 20 mL, 30 mL, 50 mL, 100 mL, and 200 mL. , 500mL, 1L, 3L, 5L, 10L, or 20L, and the upper limit is preferably 100L, 50L, 20L, 10L, 5L, 3L, 1L, 500mL, 200mL, 100mL, 50mL, or 30mL.
- the medium used for the adhesive culture is a medium containing a PKC ⁇ inhibitor and a TNKS inhibitor in the basal medium described in "1-2. Definition of terms" above.
- the medium is not limited as long as it contains a PKC ⁇ inhibitor and a TNKS inhibitor and can proliferate and / or maintain pluripotent stem cells.
- the PKC ⁇ inhibitor may be one type or a combination of two or more different types.
- the lower limit of the concentration of the PKC ⁇ inhibitor is not particularly limited and can be selected within a range that does not cause cell death.
- the PKC ⁇ inhibitor can have a final concentration of 25 nM or more, 30 nM or more, 50 nM or more, 80 nM or more, 100 nM or more as the final concentration in the liquid medium. It can be 150 nM or more, 200 nM or more, 500 nM or more, 700 nM or more.
- the upper limit of the concentration of the PKC ⁇ inhibitor is not particularly limited, and can be determined according to the range that does not cause cell death, the range that does not exhibit toxicity to pluripotent stem cells, the solubility of the PKC ⁇ inhibitor, and the like.
- the PKC ⁇ inhibitor can have a final concentration of 15 ⁇ M or less, 10 ⁇ M or less, 5 ⁇ M or less, 3 ⁇ M or less, and 1 ⁇ M or less in the liquid medium. be able to.
- the TNKS inhibitor may be one kind or a combination of two or more different kinds.
- the lower limit of the concentration of the TNKS inhibitor is not particularly limited and can be determined according to the range that does not cause cell death.
- the TNKS inhibitor can have a final concentration of 90 nM or more, 100 nM or more, 150 nM or more, 200 nM or more, 300 nM or more as the final concentration in the liquid medium. It can be 400 nM or more, 500 nM or more, 600 nM or more, 700 nM or more, 800 nM or more, 900 nM or more. can.
- the upper limit of the concentration of the TNKS inhibitor is not particularly limited, and can be determined according to the range that does not cause cell death, the range that does not exhibit toxicity to pluripotent stem cells, the solubility of the TNKS inhibitor, and the like.
- the TNKS inhibitor can have a final concentration of 40 ⁇ M or less, 35 ⁇ M or less, 30 ⁇ M or less, 15 ⁇ M or less, and 10 ⁇ M or less in the liquid medium. It can be 5 ⁇ M or less, 3 ⁇ M or less, 1.5 ⁇ M or less, and 1 ⁇ M or less.
- the lower limit of the ratio of the content concentration (molar concentration) of the PKC ⁇ inhibitor and the TNKS inhibitor in the liquid medium is not particularly limited, but is, for example, 167: 1 or more, 111: 1 or more, 56: 1 or more, 33: 1. As mentioned above, it can be 11: 1 or more, 7.8: 1 or more, 5.6: 1 or more, 2.2: 1 or more, 1.7: 1 or more, or 1.1: 1 or more.
- the upper limit of the ratio of the content concentration (molar concentration) of the PKC ⁇ inhibitor and the TNKS inhibitor in the liquid medium is not particularly limited, but is, for example, 1: 1600 or less, 1: 1400 or less, 1: 1200 or less, 1: 600 or less.
- the ratio of the content concentration (molar concentration) of the PKC ⁇ inhibitor and the TNKS inhibitor in the liquid medium is not particularly limited, but can be, for example, in the range of 167: 1 or more and 1: 1600 or less.
- the ratio of the content concentration (molar concentration) of the PKC ⁇ inhibitor and the TNKS inhibitor in the liquid medium can be preferably in the range of 111: 1 or more and 1: 1600 or less, and 56: 1 or more and 1: 1600. It can be in the following range, 33: 1 or more and 1: 1600 or less, 11: 1 or more and 1: 1600 or less, and 7.8: 1 or more and 1: 1600 or less. It can be in the following range, it can be in the range of 5.6: 1 or more and 1: 1600 or less, it can be in the range of 2.2: 1 or more and 1: 1600 or less, and it can be in the range of 1.7: 1 or more.
- the ratio of the content concentration (molar concentration) of the PKC ⁇ inhibitor and the TNKS inhibitor in the liquid medium can be in the range of 167: 1 or more and 1: 1400 or less, and in the range of 167: 1 or more and 1: 1200 or less. It can be in the range of 167: 1 or more and 1: 600 or less, in the range of 167: 1 or more and 1: 400 or less, and in the range of 167: 1 or more and 1: 200 or less.
- It can be a range of 1:12 or less, a range of 167: 1 or more and 1: 8 or less, a range of 167: 1 or more and 1: 6 or less, and a range of 167: 1 or more and 1 : It can be in the range of 4 or less.
- the method of adding the PKC ⁇ inhibitor and the TNKS inhibitor is not particularly limited.
- one or more PKC ⁇ inhibitors and TNKS inhibitors may be directly administered to the medium so that the total amount is within the above concentration range.
- the amount of the medium and the culture solution may be appropriately adjusted depending on the culture vessel used.
- the height of the liquid level from the bottom surface of the container is 2 mm.
- the area of the bottom surface of the dish in a plan view is 150 cm 2
- it can be 30 mL.
- the density of cells seeded in a new medium can be appropriately adjusted in consideration of the culture time, the cell state after culture, and the number of cells required after culture.
- the lower limit is, for example, 0.1 ⁇ 10 4 cells / cm 2 or more, 1 ⁇ 10 4 cells / cm 2 or more, or 2 ⁇ 10 4 cells / cm 2 or more
- the upper limit is For example, it is in the range of 20 ⁇ 10 4 cells / cm 2 or less, or 10 ⁇ 10 5 cells / cm 2 or less.
- Culture conditions such as culture temperature, time, and CO 2 concentration are not particularly limited. It may be done within the range of the conventional method in the field.
- the culture temperature may have a lower limit of 20 ° C. or higher, or 35 ° C. or higher, and an upper limit of 45 ° C. or lower, or 40 ° C. or lower, preferably 37 ° C.
- the culture time is, for example, in the range where the lower limit is 0.5 hours or more or 6 hours or more per passage period, and the upper limit is 8 days or less, 120 hours or less, 96 hours or less, 72 hours or less, or 48 hours or less. Is.
- the CO 2 concentration during culturing has, for example, a lower limit of 0.5% or more, 1% or more, 2% or more, 3% or more, 4% or more, or 4.5% or more, and an upper limit of 10% or less, or 5 It can be 5.5% or less, more preferably 5%.
- the CO 2 concentration during culturing does not have to be constant and may be changed or changed during culturing.
- the O 2 concentration at the time of culturing can be, for example, a lower limit of 3% or more, or 5% or more, and an upper limit of 21% or less, or 20% or less, more preferably 21%.
- the medium can be exchanged at an appropriate frequency.
- the frequency of medium exchange varies depending on the cell type to be cultured, but for example, once every 5 days or more, once every 4 days or more, once every 3 days or more, once every 2 days or more, and once a day or more. , Or more than twice a day.
- the medium may be exchanged continuously at all times by a perfusion method.
- the medium may be exchanged by collecting cells by the same method as in the recovery step described later, adding fresh medium, gently dispersing cell aggregates, and then culturing again.
- the cells and the medium may be separated by a filter and the medium may be exchanged in order to retain the cells in the culture system.
- the culture solution obtained by separating the cells from the container with a filter or the like may be continuously sucked and a new medium may be continuously added.
- the frequency and method of medium exchange are not limited to the above frequency and method, and the optimum method may be appropriately adopted.
- the adhesive culture In the adhesive culture, the flow state of the medium during the culture does not matter. That is, the adhesive culture may be a static culture or a fluid culture.
- “Standing culture” means culturing with the medium standing in a culture container. In adhesive culture, this static culture is usually adopted. "Fluid culture” refers to culturing in a state in which the medium is fluidized, and in adhesive culture, there is a method in which cells are adhered to a microcarrier or the like and cultured under the fluidity of the medium.
- the number of cells obtained by proliferation can be arbitrarily set.
- the target number of cells and the state of cells can be appropriately determined according to the type of cells to be cultured, the purpose of cell aggregation, the type of medium and the culture conditions.
- the degree of cell proliferation is not particularly limited as the occupancy rate with respect to the culture area of the culture vessel, but the lower limit may be 10% or more, 20% or more, 30% or more, 40% or more, 50% or more.
- the upper limit can be 100% or less, 90% or less, 80% or less, 70% or less, and 60% or less. In particular, it is preferable to proliferate the cells so that the lower limit is 70% or more and the upper limit is 80% or less as the occupancy rate with respect to the culture area of the culture vessel.
- pluripotent stem cells in the middle of culture can be taken out and it can be confirmed whether the undifferentiated state is maintained. For example, by measuring the degree of expression of the pluripotent stem cell marker expressed in the pluripotent stem cells taken out during culture, it is possible to confirm whether or not the undifferentiated state is maintained.
- pluripotent stem cell markers include Alkaline Phosphatase, NANOG, Oct4, SOX2, TRA-1-60, c-Myc, KLF4, LIN28, SSEA-4, SSEA-1 and the like.
- the method for detecting these pluripotent stem cell markers also includes, for example, flow cytometry.
- the positive rate of the pluripotent stem cell marker is preferably 80% or more, more preferably 90% or more, more preferably 91% or more, more preferably 92% or more, and more. It is preferably 93% or more, more preferably 94% or more, more preferably 95% or more, more preferably 96% or more, more preferably 97% or more, more preferably 98% or more, more preferably 99% or more, more preferably. When is 100%, it can be judged that the undifferentiated state is maintained.
- the undifferentiated state was measured by measuring the expression level of the trigerm marker (endoderm cell marker, mesoderm cell marker, and ectoderm cell marker) in the pluripotent stem cells taken out during the culture. You can check if you are maintaining. That is, the positive rates of these endoderm cell markers, mesoderm cell markers, and ectoderm cell markers are all preferably 20% or less, more preferably 10% or less, more preferably 9% or less, and more preferably.
- the endoderm cell marker is a gene specific to endoderm cells, and examples thereof include SOX17, FOXA2, CXCR4, AFP, GATA4, and EOMES.
- Endograft cells include tissues of organs such as gastrointestinal tract, lung, thyroid gland, pancreas, and liver, cells of secretory glands that open in the gastrointestinal tract, peritoneum, thoracic membrane, throat, ear canal, trachea, bronchus, and urinary tract ( It differentiates into the bladder, most of the urinary tract, part of the urinary tract).
- the mesoderm cell marker is a gene specific to mesoderm cells, and is, for example, TBXT (BRACHYURY), MESS1, MESS2, FOXF1, HAND1, EVX1, IRX3, CDX2, TBX6, MIXL1, ISL1, SNAI2, FOXC1. And PDGFR ⁇ and the like.
- Mesothelial cells include the mesothelium and the mesothelium, muscles, skeleton, skin dermal, connective tissue, heart, blood vessels (including vascular endothelium), blood (including blood cells), lymph vessels, and spleen that support the body cavity. It differentiates into kidneys, urinary tracts, and gonads (testis, uterus, gonad epithelium).
- the ectoderm cell marker is a gene specific to the ectoderm cell, and examples thereof include FGF5, NESTIN, SOX1, and PAX6.
- the ectodermal cells include the epithelium of the epithelium of the skin and the end of the urinary tract of men, hair, nails, skin glands (including mammary glands and sweat glands), and the epithelium of the end of the sensory organs (oral cavity, pharynx, nose, and rectum). , Salivary glands), crystal, peripheral nervous system, etc.
- a part of the ectoderm invades in a groove shape during development to form a neural tube, which is also a source of neurons and melanocytes of the central nervous system such as the brain and spinal cord.
- the degree of expression of these three germ layer markers can be measured by any detection method in the art.
- the method for measuring the expression of the three germ layer markers is not limited, but is, for example, quantitative real-time PCR analysis, RNA-Seq method, Northern. Examples thereof include hybridization or a hybridization method using a DNA array.
- the expression level of the marker gene to be measured can be converted into the relative expression level with respect to the expression level of the internal standard gene, and the expression level of the marker gene can be evaluated based on the relative expression level.
- the internal standard gene include a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene and a ⁇ -actin (ACTB) gene.
- a step of collecting pluripotent stem cells may be performed. This step is optional.
- the culture medium and the pluripotent stem cells are separated by a conventional method, and the separated pluripotent stem cells are recovered. At this time, it is preferable that the pluripotent stem cells are recovered as a single cell by exfoliation or dispersion treatment from the external matrix or the adjacent pluripotent stem cells. The specific method will be described in detail in the recovery step described later.
- the collected cells are washed as they are or, if necessary, with a buffer (including PBS buffer), saline, or medium (preferably the medium used in the next step or the basal medium), and then subjected to the next step. Just do it.
- Suspension culture step following the adhesion culture step is a step of suspension culture of the pluripotent stem cell population obtained after the adhesion culture step, and maintains undifferentiated and proliferates. Alternatively, the differentiation may be induced without maintaining the undifferentiated state.
- the cell culture method in this step basically conforms to the culture method described in "1-5-1. Adhesive culture step" described above. Therefore, here, the description common to the method described above in the adhesive culture step is omitted, and only the points characteristic of this step will be described in detail.
- the cells used in this step are cells prepared after the adhesion culture step.
- the cell type is also pluripotent stem cells as described in the adhesion culture step, and pluripotent stem cells such as iPS cells and ES cells are particularly preferable.
- the state of the cells at the time of seeding in the medium is preferably the state of a single cell.
- the culture container used for suspension culture is preferably a container having low cell adhesion to the inner surface of the container.
- the container having low cell adhesion to the inner surface of the container include a plate having a hydrophilic surface treatment with a biocompatible substance.
- NumcronTM Sphera (Thermo Fisher Scientific Co., Ltd.) can be used as a culture vessel.
- the culture may be started in a medium containing one or both of the PKC ⁇ inhibitor and the TNKS inhibitor, or the culture may be started in the medium containing the PKC ⁇ inhibitor and the TNKS inhibitor. good. Further, the suspension culture step may be started in a medium containing one or both of the PKC ⁇ inhibitor and the TNKS inhibitor, and the culture may be switched to the medium containing the PKC ⁇ inhibitor and the TNKS inhibitor in the middle of the culture. .. In addition, starting the culture in a medium containing one or both of the PKC ⁇ inhibitor and the TNKS inhibitor means that the PKC ⁇ contained in the culture medium when the pluripotent stem cells were separated from the culture medium of the adhesion culture. Although inhibitors and TNKS inhibitors may be brought in, it means that a medium containing no one or both of PKC ⁇ inhibitors and TNKS inhibitors is used for suspension culture.
- the type of medium is not particularly limited as long as it is a medium capable of proliferating and / or maintaining the cells described in "1-2. Definition of terms" above.
- the medium used in this step may be a medium that differentiates cells without maintaining them in combination with a specific additive.
- the amount of the medium and the culture solution may be appropriately adjusted depending on the culture vessel used.
- the amount per well is 0.5 mL or more and 1.5 mL or less. It can be preferably about 1.3 mL.
- the amount per well should be 1.5 mL or more, 2 mL or more, or 3 mL or more. It can be 6 mL or less, 5 mL or less, and 4 mL or less.
- the lower limit can be 10 mL or more, 15 mL or more, 20 mL or more, 25 mL or more, or 30 mL or more, and the upper limit is. It can be 50 mL or less, 45 mL or less, or 40 mL or less.
- the lower limit can be 100 mL or more, 105 mL or more, 110 mL or more, 115 mL or more, or 120 mL or more, and the upper limit can be 150 mL or less, 145 mL.
- it can be 140 mL or less, 135 mL or less, 130 mL or less, or 125 mL or less.
- the lower limit can be 250 mL or more, 260 mL or more, 270 mL or more, 280 mL or more, or 290 mL or more
- the upper limit can be 350 mL or less and 340 mL or less. , 330 mL or less, 320 mL or less, or 310 mL or less.
- the lower limit of the amount per bag is 100 mL or more, 200 mL or more, 300 mL or more, 400 mL or more, 500 mL or more, 600 mL or more, 700 mL or more, 800 mL or more, 900 mL. It can be 2000 mL or less, 1900 mL or less, 1800 mL or less, 1700 mL or less, 1600 mL or less, 1500 mL or less, 1400 mL or less, 1300 mL or less, 1200 mL or less, or 1100 mL or less.
- the lower limit of the amount per bag can be 500 mL or more, 1 L or more, 2 L or more, 3 L or more, 4 L or more, or 5 L or more, and the upper limit is 10 L.
- it can be 9 L or less, 8 L or less, 7 L or less, or 6 L or less.
- a stirring blade type reactor having an arbitrary capacity it can be within the working volume specified by each manufacturer.
- the cell density is not particularly limited, and the culture time, the cell state after the culture, and the number of cells required after the culture are determined. It can be adjusted as appropriate in consideration.
- the lower limit is usually, for example, 0.01 ⁇ 10 5 cells / mL or more, 0.1 ⁇ 10 5 cells / mL or more, 1 ⁇ 10 5 cells / mL or more, or 2 ⁇ 10 5 cells / mL.
- More than mL and the upper limit can be, for example, in the range of 20 ⁇ 10 5 cells / mL or less, or 10 ⁇ 10 5 cells / mL or less.
- the lower limit of the seeding density is in the range of 2 ⁇ 10 5 cells / mL or more
- the upper limit is in the range of 4 ⁇ 10 5 cells / mL or less.
- suspension culture In suspension culture, the flow state of the medium during culture does not matter. That is, the suspension culture may be a static culture or a fluid culture. However, fluid culture is typically adopted for suspension culture.
- Fluid culture refers to culturing under conditions in which the medium is allowed to flow as described above.
- a method of fluidizing the medium so as to promote cell aggregation is preferable. Examples of such a culture method include a swirling culture method, a shaking culture method, agitated culture, or a combination thereof.
- “Swirl culture method” refers to a method of culturing under conditions in which the medium flows so that cells gather at one point due to stress (centrifugal force, centripetal force) due to swirling flow. Specifically, the culture vessel containing the medium containing cells is swirled so as to draw a closed orbit such as a circle, an ellipse, a flat circle, or a flat ellipse along a horizontal plane.
- the turning speed is not particularly limited, but the lower limit can be, for example, 1 rpm or more, 10 rpm or more, 50 rpm or more, 60 rpm or more, 70 rpm or more, 80 rpm or more, 83 rpm or more, 85 rpm or more, or 90 rpm or more.
- the upper limit can be, for example, 200 rpm or less, 150 rpm or less, 120 rpm or less, 115 rpm or less, 110 rpm or less, 105 rpm or less, 100 rpm or less, 95 rpm or less, or 90 rpm or less.
- the amplitude of the shaker used for swirling culture is not particularly limited, but the lower limit may be, for example, 1 mm or more, 10 mm or more, or 20 mm or more.
- the upper limit can be, for example, 200 mm or less, 100 mm or less, 50 mm or less, or 30 mm or less.
- the radius of gyration during swirling culture is also not particularly limited, but is preferably set so that the amplitude is within the above range.
- the lower limit of the turning radius is, for example, 5 mm or more or 10 mm or more, and the upper limit can be, for example, 100 mm or less or 50 mm or less.
- the "rocking culture method” refers to a method of culturing under the condition of imparting a rocking flow to the medium by a linear reciprocating motion such as rocking stirring. Specifically, the culture vessel containing the medium containing the cells is shaken in a plane substantially perpendicular to the horizontal plane.
- the rocking speed is not particularly limited, but for example, when one round trip is once, the lower limit is 2 times or more, 4 times or more, 6 times or more, 8 times or more, or 10 times or more per minute, while the upper limit is 1. It may be rocked 50 times or less, 25 times or less, 20 times or less, or 15 times or less per minute.
- a swing angle is not particularly limited, but for example, the lower limit is 0.1 ° or more, 2 ° or more, 4 ° or more, 6 ° or more, or 8 ° or more, while the upper limit is 20 ° or less, 18 ° or less, 15 °. Hereinafter, it can be 12 ° or less or 10 ° or less.
- the method for producing a cell aggregate which will be described later, it is preferable to set the rocking condition within the above range because it is easy to produce a cell aggregate having an appropriate size.
- the "stirring culture method” refers to a method of culturing under the condition that the culture medium in the container is stirred by using a stirring means such as a stirrer bar or a stirring blade while the culture container is left to stand.
- stirring culture can be achieved by using a spinner flask-shaped culture vessel with stirring blades.
- Such culture vessels are commercially available and they can also be utilized. If it is a commercially available spinner flask-shaped culture container, the amount recommended by the manufacturer can be preferably used as the amount of the cell culture composition.
- the stirring speed by the stirring means is not particularly limited, but the lower limit may be 1 rpm or more, 10 rpm or more, 30 rpm or more, 50 rpm or more, or 70 rpm or more, 90 rpm or more, 110 rpm or more, 130 rpm or more.
- the upper limit can be 200 rpm or less, or 150 rpm or less.
- the number of cells obtained by proliferation can be arbitrarily set.
- the target number of cells and the state of cells can be appropriately determined according to the type of cells to be cultured, the purpose of cell aggregation, the type of medium and the culture conditions.
- the number of cells (density) obtained by proliferation can be 1 ⁇ 10 6 cells / mL.
- the size of each cell aggregate produced is not particularly limited, but when observed under a microscope, the lower limit of the maximum width size in the observation image is 30 ⁇ m or more, 40 ⁇ m or more, 50 ⁇ m or more, 60 ⁇ m or more, 70 ⁇ m or more, 80 ⁇ m.
- the upper limit may be 1000 ⁇ m or less, 900 ⁇ m or less, 800 ⁇ m or less, 700 ⁇ m or less, 600 ⁇ m or less, 500 ⁇ m or less, 400 ⁇ m or less, 300 ⁇ m, or 200 ⁇ m or less.
- Cell aggregates in this range are preferable as a cell growth environment because oxygen and nutrients are easily supplied to the cells inside.
- the size of the cell aggregate is particularly preferably such that the lower limit is 50 ⁇ m or more and the upper limit is 300 ⁇ m or less.
- the lower limit is 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 75% or more, 80% or more, 85 on a weight basis.
- % Or more, 90% or more, 95% or more, 98% or more, or 100% is preferably a cell aggregate within the above size range.
- the proportion (survival rate) of living cells among the cells constituting the population is, for example, 50% or more, 60% or more, 70% or more, 80% or more. It is preferably 90% or more.
- Cell aggregates with a viability in the above range are easy to maintain the aggregated state and are in a preferable state for cell proliferation.
- Recovery step means a step of recovering pluripotent stem cells cultured from the culture medium after the adhesion culture step or the suspension culture step.
- the recovery step is optional in the method for producing a pluripotent stem cell population according to the present invention. That is, the recovery step may be performed after the above-mentioned adhesion culture step, and then the suspension culture step may be performed, or the suspension culture step may be performed immediately after the adhesion culture step. Further, the recovery step may be performed after the above-mentioned suspension culture step, or the recovery step may not be performed.
- “Recovery (of cells)” refers to the acquisition of cells by separating the culture medium from the cells.
- the cell recovery method may be in accordance with a conventional method used in a cell culture method in the art, and is not particularly limited.
- the cells exist in a suspended state in the culture medium. Therefore, cell recovery can be achieved by removing the liquid component of the supernatant by standing or centrifuging. It can also be collected using a filtration filter, a hollow fiber separation membrane, or the like.
- the container containing the culture solution may be left in the stationary state for about 5 minutes, and the supernatant may be removed leaving the settled cells and cell aggregates. Centrifugation may be performed at a centrifugal acceleration and processing time so that the cells are not damaged by the centrifugal force.
- the lower limit of the centrifugal acceleration is not particularly limited as long as the cells can be sedimented, but may be, for example, 100 ⁇ g or more, 300 ⁇ g or more, 800 ⁇ g or more, or 1000 ⁇ g or more.
- the upper limit may be a speed at which the cells are not damaged by centrifugal force or are not easily damaged, and may be, for example, 1600 ⁇ g or less, 1500 ⁇ g or less, or 1400 ⁇ g or less.
- the lower limit of the treatment time is not particularly limited as long as the cells can be settled by the centrifugal acceleration, but may be, for example, 30 seconds or longer, 1 minute or longer, 3 minutes or longer, or 5 minutes or longer.
- the upper limit may be a time during which the cells are not damaged or are not easily damaged by the centrifugal acceleration, and may be, for example, 10 minutes or less, 8 minutes or less, 6 minutes or less, or 30 seconds or less.
- the filtrate may be removed by passing the culture solution through a non-woven fabric or a mesh filter, and the remaining cell aggregates may be collected.
- the culture solution and the cells may be separated and recovered using a device equipped with the hollow fiber separation membrane such as a cell concentration washing system (Kaneka Co., Ltd.). ..
- the collected cells can be washed if necessary.
- the cleaning method is not limited. For example, the same cleaning method as described in "Post-process treatment" in the above-mentioned adhesive culture step may be performed.
- a buffer for example, PBS buffer
- physiological saline for example, physiological saline
- a medium basic medium is preferable
- Single cell formation means to disperse a cell aggregate in which a plurality of cells adhere to each other or aggregate to each other, such as a monolayer cell fragment or a cell aggregate, to form a single free cell state.
- the single released cell state may be a state in which a single cell released from a monolayer cell fragment, a cell aggregate, or the like exists, and all of the cells constituting the monolayer cell fragment, the cell aggregate, or the like are present. The cells do not have to be in a single free state.
- a stripping agent and / or a chelating agent is used for single cell formation.
- the release agent is not particularly limited, but for example, trypsin, collagenase, pronase, hyaluronidase, elastase, commercially available Accutase (registered trademark), Accumax (registered trademark), TrypLE TM Express Enzyme (Life Technologies Japan Co., Ltd.), etc. TrypLE TM Select Enzyme (Life Technologies Japan Co., Ltd.), Dispase (registered trademark), etc. can be used.
- the lower limit of the concentration in the solution is not particularly limited as long as it can disperse the cell aggregate, but for example, 0.15% by volume or more and 0.18% by volume. As mentioned above, it may be 0.20% by volume or more, or 0.24% by volume or more.
- the upper limit of the concentration in the solution is not particularly limited as long as it is not affected by the lysis of the cells themselves, and is 0.30% by volume or less, 0.28% by volume or less, or 0.25. It may be less than or equal to the volume.
- the treatment time depends on the concentration of trypsin, but the lower limit thereof is not particularly limited as long as the cell aggregate is sufficiently dispersed by the action of trypsin, for example, 5 minutes or more, 8 minutes or more. It may be 10 minutes or more, 12 minutes or more, or 15 minutes or more.
- the upper limit of the treatment time is not particularly limited as long as it is not affected by the action of trypsin such as lysis of the cells themselves, and is, for example, 30 minutes or less, 28 minutes or less, 25 minutes or less, 22 minutes or less. , 20 minutes or less, or 18 minutes or less.
- a commercially available release agent it may be used at a concentration described in the attached protocol so that the cells can be dispersed into a single state.
- single cell formation can be promoted by applying a slight stress to a monolayer cell fragment, a cell agglomerate, or the like.
- the process of applying this stress is not particularly limited, and examples thereof include a method of pipetting cells with a solution a plurality of times.
- cells may be passed through a strainer or mesh, if desired.
- the cells that have become single cells can be recovered by removing the supernatant containing the stripping agent by standing or centrifuging.
- the collected cells may be washed if necessary.
- the conditions for centrifugation and the cleaning method may be the same as above.
- StemFit registered trademark
- AK02N Alka Chemical Industries, Ltd.
- Y-27632 Fluji Film Wako Pure Chemical Industries, Ltd.
- the day when the cells were seeded was defined as the 0th day of the culture, and on the 4th day of the culture, the cells were treated with Accutase (Innovative Cell Technology) for 5 minutes for 5 minutes, detached from the culture surface, and dispersed into a single cell by pipetting. did.
- the cells were suspended in StemFit® AK02N medium containing a final concentration of 10 ⁇ M Y-27632, and a part thereof was stained with trypan blue to measure the number of viable cells. After that, the cells were seeded in the same manner and the adhesive culture was continued.
- Example 1 Adhesive culture of human iPS cell 1383D6 strain
- Adhesive culture was carried out in the same procedure as in Comparative Example 1 except that 20 ⁇ M IWR-1-endo (Fujifilm Wako Pure Chemical Industries, Ltd.) and 1 ⁇ M LY-333531 (Cayman Chemical Industries, Ltd.) were added to the medium.
- Example 2 Quantitative real-time PCR analysis
- Quantitative real-time PCR analysis was performed according to the procedure shown below.
- Cells of Comparative Examples 1 and 1 on the 0th day of culture cells of Comparative Example 1 on the 8th, 16th, and 20th days of culture, and 8th, 16th, and 20th days of culture of Example 1.
- Cells were lysed using TRIzol TM Regent (Thermo Fisher Scientific).
- Total RNA was isolated and purified from the solution lysed with TRIzol TM Reagent using the PureLink® RNA Mini Kit (Thermo Fisher Scientific). The purified RNA was measured in concentration using BioSpec-nano (Shimadzu Corporation), and 500 ng was taken.
- the synthesized cDNA solution was diluted 100-fold with 10 mM Tris-HCl pH 8.0 (Nacalai Tesque) and added to a 384-well PCR plate (Thermo Fisher Scientific) at 5 ⁇ L / well.
- KOD SYBR® qPCR Mix Toyobo
- Forward primer prepared to 50 ⁇ M Riverse primer prepared to 50 ⁇ M
- DEPC-treated water Nacalai Tesque
- ACTB (Forward): 5'-CCTCATGAAGATCCTCACCGA-3'(SEQ ID NO: 1)
- ACTB (Reverse): 5'-TTGCCAATGGGTGACCTGG-3'(SEQ ID NO: 2)
- OCT4 (Forward): 5'-AGTGGGTGGAGGGAAGCTGACAAC-3'(SEQ ID NO: 3)
- OCT4 (Reverse): 5'-TCGTTGTGCATAGTCCGCTGCTTGA-3'(SEQ ID NO: 4)
- SOX2 (Forward): 5'-CACCAATCCCATCCACACTCAC-3'(SEQ ID NO: 5)
- SOX2 (Reverse): 5'-GCAAAGCTCCTACCCGTACCAC-3'(SEQ ID NO: 6)
- NANOG (Forward): 5'-AGCCTCCAGATAGCAAGACACTC-3'(SEQ ID NO: 7)
- NANOG (Forward): 5'-AGCCTCCAGATA
- Example 3 Flow cytometry analysis
- the 20-day-cultured cells adherently cultured in the same procedure as in Comparative Example 1 and Example 1 were treated with Accutase and dispersed into a single cell by pipetting.
- the cells were washed with PBS (phosphate buffered saline).
- fixing, permeation treatment, and blocking were performed using the eBioscience Foxp3 Transcription factor staining buffer set (Thermo Fisher Scientific).
- the cell sample was divided into four and resuspended in 50 ⁇ L each using the Buffer attached to the eBioscience Foxp3 Transcription factor stationing buffer set (Thermo Fisher Scientific).
- Fluorescently labeled anti-OCT4, anti-SOX2, and anti-NANOG antibodies are added and mixed in one, and antibodies excluding one of the above three types of fluorescently labeled antibodies are mixed in each of the three for FMO control. And said. Staining was performed at 4 ° C. in a light-shielded state for 1 hour. Table 3 shows the antibodies used and their addition amounts.
- Comparative Example 2 Transition from Adhesive Culture to Suspension Culture of Human iPS Cell 1383D6 Strain
- Human iPS cell 1383D6 strain adherently cultured in the same procedure as in Comparative Example 1 was treated with Accutase (Innovative Cell Technology) for 5 minutes on the 12th day of culture, peeled off from the culture surface, and dispersed to a single cell by pipetting. ..
- the cells were suspended in StemFit® AK02N medium containing a final concentration of 10 ⁇ M Y-27632, and a part thereof was stained with trypan blue to measure the number of viable cells.
- Cell suspensions were prepared using StemFit® AK02N medium containing a final concentration of 10 ⁇ M Y-27632 to contain 2 ⁇ 10 5 cells per mL.
- a 6-well plate for suspension culture (Sumitomo Bakelite) was seeded with 4 mL of cell suspension per well.
- the plate in which the cells were seeded was swirled on a rotary shaker at a speed of 90 rpm along a horizontal plane in a circle having a swirling width (diameter) of 25 mm, and suspension culture was performed at 37 ° C. in a 5% CO 2 environment.
- Example 4 Transition from adhesive culture to suspension culture of human iPS cell 1383D6 strain
- human iPS cell 1383D6 strain adherently cultured in the same procedure as in Example 1
- suspension culture was performed in the same procedure as in Comparative Example 2 on the 12th day of culture.
- Example 5 Measurement of cell number in suspension culture of human iPS cell 1383D6 strain
- Example 4 As shown in Table 5, in Example 4, the number of cells was larger than that in Comparative Example 2, and it was possible to prevent death when the transition from the adhesive culture to the suspension culture was performed, and it was shown that the efficiency was significantly improved. Was done.
- Comparative Example 3 Suspension culture of human iPS cell 1383D6 strain
- Human iPS cell 1383D6 strain adherently cultured in the same procedure as in Comparative Example 1 was treated with Accutase (Innovative Cell Technology) for 5 minutes on the 4th day of culture, peeled off from the culture surface, and dispersed to a single cell by pipetting. ..
- the cells were suspended in StemFit® AK02N medium containing a final concentration of 10 ⁇ M Y-27632, and a part thereof was stained with trypan blue to measure the number of viable cells.
- Cell suspensions were prepared using StemFit® AK02N medium containing a final concentration of 10 ⁇ M Y-27632 to contain 2 ⁇ 10 5 cells per mL.
- a 6-well plate for suspension culture (Sumitomo Bakelite) was seeded with 4 mL of cell suspension per well.
- the plate in which the cells were seeded was swirled on a rotary shaker at a speed of 90 rpm along a horizontal plane in a circle having a swirling width (diameter) of 25 mm, and suspension culture was performed at 37 ° C. in a 5% CO 2 environment.
- Example 6 Suspension culture of human iPS cell 1383D6 strain
- human iPS cell 1383D6 strain adherently cultured in the same procedure as in Example 1
- suspension culture was performed in the same procedure as in Comparative Example 2 on the 4th day of culture.
- Example 7 Measurement of cell number in suspension culture of human iPS cell 1383D6 strain
- Example 6 As shown in Table 6, the number of cells in Example 6 was larger than that in Comparative Example 3, and it was shown that the cells could be prevented from dying when the transition from the adhesive culture to the suspension culture was performed, and the efficiency was improved.
- Example 8 Adhesive culture of human iPS cell 1383D6 strain
- Human iPS cell 1383D6 strain Center for iPS Cell Research and Application, Kyoto University
- iMatrix-511 Motricome
- StemFit (registered trademark) AK02N (Ajinomoto Co., Inc.) was used as the medium, and the medium was exchanged on the 1st day of the culture, the 4th day of the culture, the 6th day of the culture, and the 7th day of the culture, with the day of seeding as the 0th day of the culture. rice field. Only at the time of cell seeding, Y-27632 (Fuji Film Wako Pure Chemical Industries, Ltd.) was added to the medium so that the final concentration was 10 ⁇ M.
- the cells were suspended in StemFit® AK02N medium containing Y-27632 with a final concentration of 10 ⁇ M and IWR-1-endo (Fujifilm Wako Pure Chemical Industries, Ltd.) with a final concentration of 10 ⁇ M, and a part of the cells was stained with trypan blue and live cells. The number was measured.
- the BioBLU 1c reactor Eppendorf contains Y-27632 with a final concentration of 10 ⁇ M and IWR-1-endo (Fujifilm Wako Pure Chemical Industries, Ltd.) with a final concentration of 10 ⁇ M so that the liquid volume is 320 mL and the cell density is 100,000 cells / mL.
- Cells were seeded using StemFit® AK02N medium and suspension stirring culture was started at a stirring rate of 75 rpm under a 5% CO 2 atmosphere at 37 ° C.
- Example 9 Measurement of cell number in suspension culture of human iPS cell 1383D6 strain
- the cells were suspended in StemFit® AK02N medium containing a final concentration of 10 ⁇ M Y-27632, and a part thereof was stained with trypan blue to measure the number of viable cells. The measured number of cells is shown in Table 7.
- Example 8 it was confirmed that the number of cells on the next day after subculturing to the suspension culture was remarkably large, and the number of cells was larger than the number of seeded cells. Normally, the number of cells on the next day after subculture to suspension culture is less than the number of seeded cells due to damage caused by enzymatic treatment during subculture and cells that die in a single cell state without forming aggregates. However, according to the method of the present invention, it is possible to suppress them not only in the floating swirling culture but also in the floating stirring culture, and the productivity can be remarkably improved.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
式Iにおいて、
R1は水素原子または炭素数1~3のアルコキシ基(好ましくはメトキシ基)であり、 R2は、水素原子、炭素数1~3のアルキル基(好ましくはメチル基)、又は、-N(RA)2により置換された炭素数1~3のアルキル基(好ましくは-(CH2)3-N(CH3)2)であり、
RAは独立にエチル基又はメチル基(好ましくはメチル基)であり、
R3は、
又は
RBは、水素原子、-S-C(=NH)(-NH2)により置換された炭素数2~4のアルキル基(好ましくは-(CH2)3-S-C(=NH)(-NH2))、又は
或いは、R2とRBとが一体となって下記の二価基
前記二価基に含まれる不斉炭素の立体配置は特に限定されないが、好ましくは、
RCは、-N(RD)2により置換された炭素数1~3のアルキル基(好ましくは-(CH2)-N(CH3)2)であり、
RDは独立にエチル基又はメチル基(好ましくはメチル基)である。
式Iで表される化合物の塩としては塩酸塩又は硫酸塩が例示できる。
1-1.概要
本発明に係る多能性幹細胞集団の製造方法では、先ず、プロテインキナーゼCβ(PKCβ)阻害剤及びタンキレース(TNKS)阻害剤を含有する液体培地にて多能性幹細胞を接着培養し、その後、浮遊培養へと移行して多能性幹細胞集団を製造する。本発明に係る多能性幹細胞集団の製造方法により、接着培養から浮遊培養に移行する際に生じる多能性幹細胞の死滅が防止され、効率的に多能性幹細胞集団を製造することができる。
本明細書で使用する以下の用語について定義する。
≪細胞≫
本明細書において発明の対象となる「多能性幹細胞」とは、生体を構成する全ての種類の細胞に分化することができる多分化能(多能性)を有し、適切な条件下のインビトロ(in vitro)での培養において多能性を維持したまま無限に増殖を続けることができる細胞をいう。より具体的に、多能性とは、個体を構成する胚葉(脊椎動物では外胚葉、中胚葉及び内胚葉の三胚葉)に分化できる能力を意味する。このような細胞は、例えば、胚性幹細胞(ES細胞:embryonic stem cell)、胚性生殖幹細胞(EG細胞:embryonic germ cell)、生殖系幹細胞(GS細胞:germline stem cell)、そして人工多能性幹細胞(iPS細胞:induced pluripotent stem cells)等が挙げられる。「ES細胞」とは、初期胚より調製された多能性幹細胞である。「EG細胞」とは、胎児の始原生殖細胞より調製された多能性幹細胞である(Shamblott M.J.et al.,1998,Proc.Natl.Acad.Sci.USA.,95:13726-13731)。「GS細胞」とは、細胞精巣より調製された多能性幹細胞である(Conrad S.,2008,Nature,456:344-349)。また、「iPS細胞」とは、分化済みの体細胞に少数の初期化因子をコードする遺伝子を導入することによって体細胞を未分化状態にするリプログラミングされた多能性幹細胞をいう。
本明細書において「細胞凝集塊」とは、浮遊培養において細胞凝集によって形成される塊状の細胞集団であって、スフェロイドとも呼ばれる。細胞凝集塊は、通常、略球状を呈する。細胞凝集塊を構成する細胞は、1種類以上の前記細胞であれば特に限定されない。例えば、ヒト多能性幹細胞又はヒト胚性幹細胞等の多能性幹細胞で構成された細胞凝集塊は、多能性幹細胞マーカーを発現している、及び/又は、多能性幹細胞マーカーが陽性を呈する細胞を含む。また、細胞塊はマイクロキャリアを介して形成されたものでもよい。
「接着培養」とは、細胞培養方法の一つで、細胞を培養容器等の外部マトリクス等に接着させて、典型的には単層で増殖させることをいう。外部マトリクスとは、特に限定されないが、例えば、Laminin、Vitronectin、Gelatin、Collagen、E-Cadherinキメラ抗体等を使用することができる。なお、細胞培養法には、接着培養とは異なる他の培養方法として、浮遊培養法がある。「浮遊培養」とは、培地中で細胞を浮遊状態で増殖させることをいう。本明細書において「浮遊状態」とは、培養液中で細胞が培養容器等に対して固定されていない、非接着の状態をいう。また、例えば、マイクロキャリアに細胞を付着させ培養液中で浮遊させた状態で培養する培養法は、細胞がマイクロキャリアに接着してはいるが、マイクロキャリアを含む細胞塊としては培養容器に接着することなく浮遊しており、浮遊培養と見なすことができる。「浮遊培養法」は、細胞を浮遊培養する方法であって、この方法での細胞は、一般的に、培養液中で凝集した細胞塊で存在する。なお、前述の細胞は、通常、接着培養のみならず、浮遊培養での培養も可能である。
本明細書において「プロテインキナーゼCβ(PKCβ)阻害剤」とは、PKCβの活性を阻害又は抑制する物質を意味する。プロテインキナーゼは、C末端側の触媒領域及びN末端側の調節領域を有している。触媒領域は、基質タンパク質上のリン酸化残基を認識する配列と、ATP/Mg2+結合する配列とから構成される。調節領域はC1ドメインとC2ドメインから構成される。
R1は水素原子または炭素数1~3のアルコキシ基(好ましくはメトキシ基)であり、
R2は、水素原子、炭素数1~3のアルキル基(好ましくはメチル基)、又は、-N(RA)2により置換された炭素数1~3のアルキル基(好ましくは-(CH2)3-N(CH3)2)であり、
RAは独立にエチル基又はメチル基(好ましくはメチル基)であり、
R3は、
又は
RBは、水素原子、-S-C(=NH)(-NH2)により置換された炭素数2~4のアルキル基(好ましくは-(CH2)3-S-C(=NH)(-NH2))、又は
或いは、R2とRBとが一体となって下記の二価基
前記二価基に含まれる不斉炭素の立体配置は特に限定されないが、好ましくは、
RCは、-N(RD)2により置換された炭素数1~3のアルキル基(好ましくは-(CH2)-N(CH3)2)であり、
RDは独立にエチル基又はメチル基(好ましくはメチル基)である。
本明細書において「タンキレース(TNKS)阻害剤」とは、タンキレースの活性を阻害又は抑制する物質を意味する。タンキレース(タンキラーゼと称する場合もある)は、標的タンパク質をポリ(ADP-リボシル)化するポリ(ADP-リボシル)化酵素(PARP)ファミリーに属し、タンキレース1(tankyrase-1/PARP-5a)及びタンキレース2(tankyrase-2/PARP-5b)が知られている。タンキレースについては、テロメア蛋白質TRF1をポリ(ADP-リボシル)化し、これをテロメアから遊離させることにより、テロメラーゼによるテロメア伸長を促進する機能が知られている。
本発明に係る多能性幹細胞集団の製造方法は、先ず、多能性幹細胞集団を接着培養し、その後、浮遊培養に移行する。特に、接着培養に使用する液体培地が上記1-2.で定義したPKCβ阻害剤及びTNKS阻害剤を有効成分として含有する。よって、本発明の一態様としては、PKCβ阻害剤及びTNKS阻害剤を有効成分として含有する、接着培養用多能性幹細胞死滅抑制剤となる。
本発明の多能性幹細胞集団の製造方法によれば、接着培養によって多能性幹細胞を培養し、その後、多能性幹細胞を浮遊培養したときに多能性幹細胞の死滅を抑制することができる。多能性幹細胞の死滅を抑制するとは、接着培養後の多能性幹細胞を浮遊培養したときの細胞数を高く維持できることと同義である。すなわち、PKCβ阻害剤とTNKS阻害剤の存在下で接着培養し、その後、浮遊培養したときの細胞数と、PKCβ阻害剤とTNKS阻害剤のいずれか一方又は両方の非存在下で接着培養し、その後、同条件で浮遊培養したときの細胞数を比べると、PKCβ阻害剤とTNKS阻害剤の存在下で接着培養したときの方が高いこととなる。
本態様の方法は、接着培養工程と、その後の浮遊培養工程を含んでいる。また、本態様の方法は回収工程を含むものでもよい。以下、それぞれの工程について、説明をする。
「接着培養工程」は、浮遊培養工程前の細胞集団を、未分化状態を維持した状態で細胞を増殖させるために培養する工程である。接着培養は、当該分野で既知の動物細胞培養法を利用することができる。例えば、細胞を容器、担体等培養基材に接着させながら培養する接着培養であってよい。
(細胞)
本工程で使用する細胞は、接着培養が可能で、かつ後述の浮遊培養において細胞凝集が可能な細胞である。前述の「1-2.用語の定義」における「培養及び培地」の項で記載したように、動物細胞が好ましく、ヒト細胞はより好ましい。また、細胞の種類は、多能性幹細胞であり、iPS細胞やES細胞のような多能性幹細胞は特に好ましい。本工程で使用する多能性幹細胞は、一つの細胞でも良いし、複数細胞からなる細胞集団(多能性幹細胞集団)でもよい。前記多能性幹細胞が多能性幹細胞集団の場合、前記集団において多能性幹細胞マーカー(例えばOCT4、SOX2、NANOG)を発現する、及び/または、多能性幹細胞マーカーが陽性を呈する細胞の割合(比率)は、例えば90%以上、91%以上、92%以上、93%以上、94%以上、95%以上、96%以上、97%以上、98%以上、99%以上、100%である。
接着培養に用いる培養容器は、特に限定されないが、容器内面にタンパク質の吸着を抑える処理をしていない容器が好ましく、外部マトリクスをコーティングできるものが好ましい。培養容器の形状は特に限定されないが、例えば、ディッシュ状、フラスコ状、ウェル状、バッグ状、スピナーフラスコ状等の形状の培養容器が挙げられる。例えば、細胞培養用シャーレ(住友ベークライト株式会社)を培養容器として使用できる。
接着培養に使用する培地は、上記「1-2.用語の定義」で説明した基礎培地にPKCβ阻害剤及びTNKS阻害剤を含む培地である。PKCβ阻害剤及びTNKS阻害剤を含み、かつ多能性幹細胞を増殖及び/又は維持できる培地であれば、限定はしない。特に、白血病阻止因子を含まない培地を使用することが好ましい。PKCβ阻害剤は、1種、又は異なる2種以上の組み合わせであってもよい。PKCβ阻害剤の濃度の下限は、特に限定されず、細胞死を生じさせない範囲で選択することができる。
接着培養に際して、新たな培地に播種する細胞の密度(播種密度)は、培養時間や培養後の細胞状態、培養後に必要な細胞数を勘案して適宜調整することができる。限定はしないが、通常、下限は、例えば、0.1×104cells/cm2以上、1×104cells/cm2以上、又は2×104cells/cm2以上、そして、上限は、例えば、20×104cells/cm2以下、又は10×105cells/cm2以下の範囲である。
培養温度、時間、CO2濃度等の培養条件は特に限定しない。当該分野における常法の範囲で行えばよい。例えば、培養温度は下限が20℃以上、又は35℃以上、そして上限が45℃以下、又は40℃以下であればよく、好ましくは37℃である。また、培養時間は、例えば、1継代期間あたり下限が0.5時間以上又は6時間以上、そして上限が8日間以下、120時間以下、96時間以下、72時間以下、又は48時間以下の範囲である。培養時のCO2濃度は、例えば、下限が0.5%以上、1%以上、2%以上、3%以上、4%以上、又は4.5%以上、そして上限が10%以下、又は5.5%以下とすることができ、5%とすることがより好ましい。なお、培養時のCO2濃度は一定である必要はなく、培養途中で変更・変化してもよい。培養時のO2濃度は、例えば、下限が3%以上、又は5%以上、そして上限が21%以下、又は20%以下とすることができ、21%とすることがより好ましい。また、接着培養においては、適当な頻度で培地交換を行うことができる。培地交換の頻度は、培養する細胞種によって異なるが、例えば、5日に1回以上、4日に1回以上、3日に1回以上、2日に1回以上、1日に1回以上、又は1日に2回以上とすることができる。また、灌流方式で常に連続して培地交換を行ってもよい。培地交換は、後述する回収工程と同様の方法で細胞を回収した後、新鮮な培地を添加し、穏やかに細胞凝集塊を分散させた後、再度培養すればよい。灌流方式で培地交換を行う場合は、培養系中に細胞を留めるためにフィルターで細胞と培地を分離し培地交換すればよい。または、培養を継続しつつ容器内から細胞をフィルター等で分離した培養液を連続的に吸引し、かつ新しい培地を連続的に流加すればよい。なお、培地交換の頻度や方法等については、上記の頻度や方法には限定されず、適宜最適な方法を採用すればよい。
接着培養において、培養中の培地の流動状態は問わない。すなわち、接着培養は、静置培養でもよいし、流動培養でもよい。
上述した接着培養工程の後、多能性幹細胞を回収する工程を行っても良い。本工程は任意である。多能性幹細胞を回収する工程では、常法により培養液と多能性幹細胞とを分離し、分離した多能性幹細胞を回収する。この時、多能性幹細胞は、外部マトリックスや隣接する多能性幹細胞から剥離又は分散処理によって単一の細胞として回収することが好ましい。具体的な方法については、後述の回収工程で詳述する。回収した細胞は、そのまま、又は必要に応じてバッファ(PBSバッファを含む)、生理食塩水、又は培地(次の工程で使用する培地か基礎培地が好ましい)で洗浄後、次の工程に供すればよい。
上述した接着培養工程の後に行う「浮遊培養工程」は、接着培養工程後に得られる多能性幹細胞集団を浮遊培養する工程であり、未分化を維持し増殖させてもよく、また未分化を維持せず分化誘導を行ってもよい。PKCβ阻害剤及びTNKS阻害剤を含む培地で接着培養した多能性幹細胞を浮遊培養することによって、本工程開始時の細胞数維持率を高く保つことができ、その後の生産効率を向上することができる。
本工程で使用する細胞は、接着培養工程後に調製された細胞である。細胞の種類も、接着培養工程に記載のように、多能性幹細胞であり、iPS細胞やES細胞のような多能性幹細胞は特に好ましい。また培地に播種する際の細胞の状態は、単一細胞の状態であることが好ましい。
浮遊培養に用いる培養容器は、容器内面への細胞の接着性が低い容器が好ましい。容器内面への細胞の接着性が低い容器としては、例えば生体適合性がある物質で親水性表面処理されているようなプレートが挙げられる。例えば、NunclonTM Sphera(サーモフィッシャーサイエンティフィック株式会社)を培養容器として使用できる。
本浮遊培養工程では、PKCβ阻害剤及びTNKS阻害剤のいずれか一方又は両方を含まない培地で培養を開始しても良いし、PKCβ阻害剤及びTNKS阻害剤を含む培地で培養を開始しても良い。また、本浮遊培養工程をPKCβ阻害剤及びTNKS阻害剤のいずれか一方又は両方を含まない培地で培養を開始し、途中でPKCβ阻害剤及びTNKS阻害剤を含む培地に切り替えて培養しても良い。なお、PKCβ阻害剤及びTNKS阻害剤のいずれか一方又は両方を含まない培地で培養を開始するとは、接着培養の培養液から多能性幹細胞を分離する際に当該培養液に含まれていたPKCβ阻害剤及びTNKS阻害剤が持ち込まれることはあっても、浮遊培養に際してはPKCβ阻害剤及びTNKS阻害剤のいずれか一方又は両方を含まない培地を使用するという意味である。
浮遊培養に際して、接着培養した多能性幹細胞を新たな培地に播種する際、細胞の密度(播種密度)は、特に限定されず、培養時間や培養後の細胞状態、培養後に必要な細胞数を勘案して適宜調整することができる。限定はしないが、通常、下限は、例えば、0.01×105cells/mL以上、0.1×105cells/mL以上、1×105cells/mL以上、又は2×105cells/mL以上、そして、上限は、例えば、20×105cells/mL以下、又は10×105cells/mL以下の範囲とすることができる。特に好ましくは、播種密度の下限は2×105cells/mL以上、上限は4×105cells/mL以下の範囲である。
浮遊培養において、培養中の培地の流動状態は問わない。すなわち、浮遊培養は、静置培養でもよいし、流動培養でもよい。ただし、典型的に浮遊培養では流動培養が採用される。
「回収工程」は、接着培養工程または浮遊培養工程後の培養液から培養した多能性幹細胞を回収する工程を意味する。本発明に係る多能性幹細胞集団の製造方法において回収工程は任意である。すなわち、上述した接着培養工程の後に回収工程を行い、その後、浮遊培養工程を行っても良いし、接着培養工程の後に直ちに浮遊培養工程を行っても良い。また、上述した浮遊培養工程の後に回収工程を行っても良いし、回収工程を行わなくても良い。「(細胞の)回収」とは、培養液と細胞とを分離して細胞を取得することをいう。細胞の回収方法は、当該分野の細胞培養法で使用される常法に従えばよく、特に限定はしない。
また、接着培養工程又は浮遊培養工程の後に回収した多能性幹細胞は、「単一細胞化」することができる。単一細胞化とは、単層細胞片や細胞凝集塊等のように複数の細胞が互いに接着又は凝集した細胞集合体を分散させて、単一の遊離した細胞状態にすることをいう。なお、単一の遊離した細胞状態とは、単層細胞片や細胞凝集塊等から遊離した単一の細胞が存在する状態とすればよく、単層細胞片や細胞凝集塊等を構成する全ての細胞が単一の遊離した状態となる必要は無い。
(比較例1:ヒトiPS細胞1383D6株の接着培養)
Vitronectin(VTN-N)Recombinant Human Protein,Truncated(サーモフィッシャーサイエンティフィック社)を0.5μg/cm2でコーティングした細胞培養用ディッシュに、ヒトiPS細胞1383D6株(京都大学iPS細胞研究所)を10000cells/cm2で播種し、37℃、5%CO2雰囲気下で接着培養を行った。培地はStemFit(登録商標)AK02N(味の素社)を使用し、毎日培地交換を行った。細胞播種時のみY-27632(富士フイルム和光純薬社)を最終濃度が10μMとなるように培地に添加した。細胞を播種した日を培養0日目とし、培養4日目に継代のためAccutase(イノベーティブセルテクノロジー社)で細胞を5分間処理して培養面から剥離し、ピペッティングによって単一細胞に分散した。この細胞を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地で懸濁し、その一部をトリパンブルー染色して生細胞数を測定した。その後同様に細胞を播種し接着培養を継続した。
培地に20μMのIWR-1―endo(富士フイルム和光純薬社)と1μMのLY-333531(ケイマンケミカル社)を添加した以外は、比較例1と同様の手順で接着培養した。
以下に示す手順で定量的リアルタイムPCR解析を行った。比較例1及び実施例1の培養0日目の細胞、比較例1の培養8日目、16日目、20日目の細胞、実施例1の培養8日目、16日目、20日目の細胞をTRIzolTMReagent(サーモフィッシャーサイエンティフィック社)を用いて溶解させた。PureLink(登録商標)RNA Miniキット(サーモフィッシャーサイエンティフィック社)を用いて、TRIzolTM Reagentで溶解させた溶液からtotal RNAを単離及び精製した。精製したRNAをBioSpec-nano(島津製作所社)を用いて濃度測定し、500ng分取した。分取したRNAに対し、ReverTra Ace(登録商標)qPCR RT Master mix(東洋紡社)を2μLとRnase Free dH2Oを添加して10μLに調製し、SimpliAmp Thermal Cycler(サーモフィッシャーサイエンティフィック社)を用いてcDNA合成を行った。cDNA合成の反応条件は、37℃で15分反応後、50℃で5分反応、98℃で5分反応を連続して行い、4℃に冷却した。合成したcDNA溶液を10mM Tris-HCl pH8.0(ナカライテスク社)で100倍に希釈し、384well PCRプレート(サーモフィッシャーサイエンティフィック社)に5μL/wellで添加した。KOD SYBR(登録商標)qPCR Mix(東洋紡社)、50μMに調製したForwardプライマー、50μMに調製したReverseプライマー、DEPC処理水(ナカライテスク社)を100:1:1:48の割合で混合し、この混合液を15μL/wellで前記384well PCRプレートに添加して混合した。プライマーはACTB、OCT4、SOX2、NANOG、TFCP2L1、OTX2、KLF4、PAX6、BRCHYURY、SOX17を用いた。384well PCRプレートを遠心分離してウェル内の気泡を除去し、QuantStudio 7 Flex Real-Time PCR System(サーモフィッシャーサイエンティフィック社)を用いて定量的リアルタイムPCR解析を実施した。反応条件を表1に示す。
ACTB(Forward):5’-CCTCATGAAGATCCTCACCGA-3’(配列番号1)
ACTB(Reverse):5’-TTGCCAATGGTGATGACCTGG-3’(配列番号2)
OCT4(Forward):5’-AGTGGGTGGAGGAAGCTGACAAC-3’(配列番号3)
OCT4(Reverse):5’-TCGTTGTGCATAGTCGCTGCTTGA-3’(配列番号4)
SOX2(Forward):5’-CACCAATCCCATCCACACTCAC-3’(配列番号5)
SOX2(Reverse):5’-GCAAAGCTCCTACCGTACCAC-3’(配列番号6)
NANOG(Forward):5’-AGCCTCCAGCAGATGCAAGAACTC-3’(配列番号7)
NANOG(Reverse):5’-TTGCTCCACATTGGAAGGTTCCCA-3’(配列番号8)
比較例1、実施例1と同様の手順で接着培養した培養20日目細胞を、Accutaseで処理し、ピペッティングによって単一細胞まで分散させた。この細胞をPBS(リン酸緩衝生理食塩水)で洗浄した。その後、eBioscience Foxp3 Transcription factor staining buffer set(サーモフィッシャーサイエンティフィック社)を用いて固定・透過処理・ブロッキングを行った。その後、細胞のサンプルを4つに分けてそれぞれ50μLずつにeBioscience Foxp3 Transcription factor staining buffer set(サーモフィッシャーサイエンティフィック社)付属のBufferを用いて再懸濁した。1つに蛍光標識済抗OCT4、抗SOX2、及び抗NANOG抗体をそれぞれ加えて混合し、3つにはそれぞれ上記3種の蛍光標識済抗体のうち1種ずつを除いた抗体を混合しFMOコントロールとした。4℃、遮光状態で1時間染色した。使用した抗体とその添加量を表3に示した。
比較例1と同じ手順で接着培養したヒトiPS細胞1383D6株を培養12日目にAccutase(イノベーティブセルテクノロジー社)で5分間処理して培養面から剥離し、ピペッティングによって単一細胞まで分散させた。この細胞を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地で懸濁し、その一部をトリパンブルー染色して生細胞数を測定した。細胞懸濁液を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地を用いて1mLあたり2×105個の細胞を含むように調製した。浮遊培養用6ウェルプレート(住友ベークライト社)に1ウェルあたり4mLの細胞懸濁液を播種した。細胞を播種したプレートはロータリーシェーカー上で90rpmの速度で水平面に沿って旋回幅(直径)が25mmの円を描くように旋回させ、37℃、5%CO2環境下で浮遊培養を行った。
実施例1と同じ手順で接着培養したヒトiPS細胞1383D6株を用いて培養12日目に比較例2と同様の手順で浮遊培養を行った。
比較例2、実施例4の方法で接着培養から浮遊培養に細胞を継代した翌日にウェルから細胞凝集塊と培養上清を遠沈管に回収し、5分程度静置して細胞凝集塊を沈降させて培養上清を除去した。細胞凝集塊にAccutaseを1mL添加して37℃で10分間処理した後、ピペッティングによって単一細胞まで分散させた。この細胞を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地で懸濁し、その一部をトリパンブルー染色して生細胞数を測定した。測定した細胞数を、表5に示す。
比較例1と同じ手順で接着培養したヒトiPS細胞1383D6株を培養4日目にAccutase(イノベーティブセルテクノロジー社)で5分間処理して培養面から剥離し、ピペッティングによって単一細胞まで分散させた。この細胞を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地で懸濁し、その一部をトリパンブルー染色して生細胞数を測定した。細胞懸濁液を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地を用いて1mLあたり2×105個の細胞を含むように調製した。浮遊培養用6ウェルプレート(住友ベークライト社)に1ウェルあたり4mLの細胞懸濁液を播種した。細胞を播種したプレートはロータリーシェーカー上で90rpmの速度で水平面に沿って旋回幅(直径)が25mmの円を描くように旋回させ、37℃、5%CO2環境下で浮遊培養を行った。
実施例1と同じ手順で接着培養したヒトiPS細胞1383D6株を用いて培養4日目に比較例2と同様の手順で浮遊培養を行った。
比較例3、実施例6の方法で接着培養から浮遊培養に細胞を継代した翌日にウェルから細胞凝集塊と培養上清を遠沈管に回収し、5分程度静置して細胞凝集塊を沈降させて培養上清を除去した。細胞凝集塊にAccutaseを1mL添加して37℃で10分間処理した後、ピペッティングによって単一細胞まで分散させた。この細胞を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地で懸濁し、その一部をトリパンブルー染色して生細胞数を測定した。測定した細胞数を、表6に示す。
iMatrix-511(マトリクソーム社)を0.5μg/cm2でコーティングした細胞培養用フラスコに、ヒトiPS細胞1383D6株(京都大学iPS細胞研究所)を1000cells/cm2で播種し、37℃、5%CO2雰囲気下で接着培養を行った。培地はStemFit(登録商標)AK02N(味の素社)を使用し、播種した日を培養0日目として、培養1日目、培養4日目、培養6日目、培養7日目に培地交換を行った。細胞播種時のみY-27632(富士フイルム和光純薬社)を最終濃度が10μMとなるように培地に添加した。培養4日目以降の培地交換では、20μMのIWR-1―endo(富士フイルム和光純薬社)と1μMのLY-333531(ケイマンケミカル社)を添加したStemFit(登録商標)AK02N(味の素社)を使用した。培養8日目に継代のためTrypLE SELECT(サーモフィッシャーサイエンティフィック社)で細胞を処理して培養面から剥離し、ピペッティングによって単一細胞に分散した。この細胞を最終濃度10μMのY-27632と20μMのIWR-1―endo(富士フイルム和光純薬社)を含むStemFit(登録商標)AK02N培地で懸濁し、その一部をトリパンブルー染色して生細胞数を測定した。その後、BioBLU 1c リアクター(エッペンドルフ社)に液量は320mL、細胞密度は100000cells/mLとなるように最終濃度10μMのY-27632と20μMのIWR-1―endo(富士フイルム和光純薬社)を含むStemFit(登録商標)AK02N培地を用いて細胞を播種し、37℃、5%CO2雰囲気下で75rpmの攪拌速度で浮遊攪拌培養を開始した。
実施例8の方法で接着培養から浮遊培養に細胞を継代した翌日にリアクターから培養液3mLを遠沈管に回収し、5分程度静置して細胞凝集塊を沈降させて培養上清を除去した。細胞凝集塊にAccutaseを1mL添加して37℃で10分間処理した後、ピペッティングによって単一細胞まで分散させた。この細胞を最終濃度10μMのY-27632を含むStemFit(登録商標)AK02N培地で懸濁し、その一部をトリパンブルー染色して生細胞数を測定した。測定した細胞数を、表7に示す。
Claims (12)
- PKCβ阻害剤及びTNKS阻害剤を含む液体培地中で、多能性幹細胞を接着培養する工程と、
接着培養後の多能性幹細胞を浮遊培養する工程と
を含む、多能性幹細胞集団の製造方法。 - 前記液体培地中のPKCβ阻害剤含有濃度が、25nM以上15μM以下である請求項1記載の方法。
- 前記液体培地中のTNKS阻害剤含有濃度が、90nM以上40μM以下である請求項1記載の方法。
- 前記液体培地が、L-アスコルビン酸、インスリン、トランスフェリン、セレン及び炭酸水素ナトリウムからなる群より選ばれる少なくとも1つを含有する請求項1記載の方法。
- 前記液体培地が、FGF2及び/又はTGF-β1を含む請求項1記載の方法。
- 前記液体培地が、ROCK阻害剤を含有する請求項1記載の方法。
- 前記ROCK阻害剤が、Y-27632である請求項6記載の方法。
- 前記浮遊培養する工程が、細胞凝集塊を形成する工程を含む請求項1記載の方法。
- 前記浮遊培養する工程が、細胞凝集塊を回収する工程を含む請求項1記載の方法。
- 前記多能性幹細胞集団は、OCT4が陽性を呈する細胞の比率が90%以上であり、SOX2が陽性を呈する細胞の比率が90%以上であり、NANOGが陽性を呈する細胞の比率が90%以上である請求項1記載の方法。
- 前記多能性幹細胞が、ES細胞及び/又は人工多能性幹細胞である請求項1記載の方法。
- 前記多能性幹細胞を浮遊培養する工程では、PKCβ阻害剤及び/又はTNKS阻害剤を含まない液体培地に、接着培養後の多能性幹細胞を接種することを特徴とする請求項1記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/265,609 US20240035000A1 (en) | 2020-12-07 | 2021-12-07 | Method for producing pluripotent stem cell population |
JP2022568288A JPWO2022124298A1 (ja) | 2020-12-07 | 2021-12-07 | |
EP21903397.4A EP4257678A1 (en) | 2020-12-07 | 2021-12-07 | Production method for producing pluripotent stem cell population |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020202566 | 2020-12-07 | ||
JP2020-202566 | 2020-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022124298A1 true WO2022124298A1 (ja) | 2022-06-16 |
Family
ID=81974577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/044881 WO2022124298A1 (ja) | 2020-12-07 | 2021-12-07 | 多能性幹細胞集団を製造する製造方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240035000A1 (ja) |
EP (1) | EP4257678A1 (ja) |
JP (1) | JPWO2022124298A1 (ja) |
WO (1) | WO2022124298A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023149495A1 (ja) * | 2022-02-04 | 2023-08-10 | 国立研究開発法人理化学研究所 | 人工多能性幹細胞の製造方法 |
WO2024101385A1 (ja) * | 2022-11-09 | 2024-05-16 | 株式会社カネカ | 多能性幹細胞の製造方法及び多能性幹細胞に対する分化誘導方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012175962A (ja) | 2011-01-31 | 2012-09-13 | National Institute Of Biomedical Innovation | ヒト多能性幹細胞の培養方法 |
WO2013183777A1 (ja) | 2012-06-08 | 2013-12-12 | 独立行政法人理化学研究所 | ヒトes細胞用培養容器 |
WO2016016894A1 (en) * | 2014-07-30 | 2016-02-04 | Yeda Research And Development Co. Ltd. | Media for culturing pluripotent stem cells |
WO2016121737A1 (ja) * | 2015-01-29 | 2016-08-04 | 株式会社カネカ | 細胞凝集塊の作製方法 |
WO2018015954A1 (en) * | 2016-07-19 | 2018-01-25 | Accellta Ltd. | Culture media for culturing pluripotent stem cells in suspension |
WO2018047941A1 (ja) | 2016-09-08 | 2018-03-15 | 協和発酵バイオ株式会社 | 幹細胞培養用培地、幹細胞の培養方法、幹細胞の増殖促進剤、並びに細胞組成物およびその製造方法 |
WO2019151386A1 (ja) | 2018-01-31 | 2019-08-08 | 富士フイルム株式会社 | 細胞の製造方法 |
WO2020039732A1 (ja) | 2018-08-24 | 2020-02-27 | 住友化学株式会社 | 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法 |
WO2020203532A1 (ja) * | 2019-03-29 | 2020-10-08 | 株式会社カネカ | 多能性幹細胞の製造方法 |
-
2021
- 2021-12-07 EP EP21903397.4A patent/EP4257678A1/en active Pending
- 2021-12-07 WO PCT/JP2021/044881 patent/WO2022124298A1/ja active Application Filing
- 2021-12-07 JP JP2022568288A patent/JPWO2022124298A1/ja active Pending
- 2021-12-07 US US18/265,609 patent/US20240035000A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012175962A (ja) | 2011-01-31 | 2012-09-13 | National Institute Of Biomedical Innovation | ヒト多能性幹細胞の培養方法 |
WO2013183777A1 (ja) | 2012-06-08 | 2013-12-12 | 独立行政法人理化学研究所 | ヒトes細胞用培養容器 |
WO2016016894A1 (en) * | 2014-07-30 | 2016-02-04 | Yeda Research And Development Co. Ltd. | Media for culturing pluripotent stem cells |
WO2016121737A1 (ja) * | 2015-01-29 | 2016-08-04 | 株式会社カネカ | 細胞凝集塊の作製方法 |
WO2018015954A1 (en) * | 2016-07-19 | 2018-01-25 | Accellta Ltd. | Culture media for culturing pluripotent stem cells in suspension |
WO2018047941A1 (ja) | 2016-09-08 | 2018-03-15 | 協和発酵バイオ株式会社 | 幹細胞培養用培地、幹細胞の培養方法、幹細胞の増殖促進剤、並びに細胞組成物およびその製造方法 |
WO2019151386A1 (ja) | 2018-01-31 | 2019-08-08 | 富士フイルム株式会社 | 細胞の製造方法 |
WO2020039732A1 (ja) | 2018-08-24 | 2020-02-27 | 住友化学株式会社 | 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法 |
WO2020203532A1 (ja) * | 2019-03-29 | 2020-10-08 | 株式会社カネカ | 多能性幹細胞の製造方法 |
Non-Patent Citations (5)
Title |
---|
CONRAD S., NATURE, vol. 456, 2008, pages 344 - 349 |
OLMER R, TISSUE ENGINEERING: PART C, vol. 18, no. 10, 2012, pages 772 - 784 |
SHAMBLOTT M. J. ET AL., PROC. NATL. ACAD. SCI., U.S.A., vol. 95, 1998, pages 13726 - 13731 |
TAKAHASHI K ET AL., CELL, vol. 131, 2007, pages 861 - 72 |
YU J, SCIENCE, vol. 318, 2007, pages 1917 - 20 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023149495A1 (ja) * | 2022-02-04 | 2023-08-10 | 国立研究開発法人理化学研究所 | 人工多能性幹細胞の製造方法 |
WO2024101385A1 (ja) * | 2022-11-09 | 2024-05-16 | 株式会社カネカ | 多能性幹細胞の製造方法及び多能性幹細胞に対する分化誘導方法 |
Also Published As
Publication number | Publication date |
---|---|
US20240035000A1 (en) | 2024-02-01 |
JPWO2022124298A1 (ja) | 2022-06-16 |
EP4257678A1 (en) | 2023-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021162090A1 (ja) | 多能性幹細胞の分化抑制方法 | |
JP6983762B2 (ja) | 臨床グレードの網膜色素上皮細胞の再現性のある分化のための方法 | |
JP5227318B2 (ja) | 細胞増殖培地 | |
WO2022124298A1 (ja) | 多能性幹細胞集団を製造する製造方法 | |
JP6864670B2 (ja) | 網膜色素上皮細胞の調製法 | |
JP7336386B2 (ja) | 多能性幹細胞凝集抑制剤 | |
JP6238265B2 (ja) | 細胞凝集塊の作製方法 | |
US20100183566A1 (en) | METHOD FOR EFFICIENT TRANSFER OF HUMAN BLASTOCYST-DERIVED STEM CELLS (hBS CELLS) FROM A FEEDER-SUPPORTED TO A FEEDER-FREE CULTURE SYSTEM | |
EP2882848B1 (en) | Method, combination and/or composition for inducing cardiomyocyte differentation | |
WO2020203532A1 (ja) | 多能性幹細胞の製造方法 | |
WO2020203538A1 (ja) | 多能性幹細胞を含む細胞集団及びその製造方法 | |
JP7349911B2 (ja) | 細胞凝集促進剤 | |
JP2021126065A (ja) | 細胞凝集促進剤 | |
WO2023017806A1 (ja) | 多能性幹細胞の製造方法 | |
WO2019131941A1 (ja) | 細胞凝集抑制剤 | |
WO2024101385A1 (ja) | 多能性幹細胞の製造方法及び多能性幹細胞に対する分化誘導方法 | |
JP2011152111A (ja) | 多能性幹細胞培養用培地 | |
WO2023149495A1 (ja) | 人工多能性幹細胞の製造方法 | |
JP7477983B2 (ja) | 細胞凝集抑制剤 | |
JP2023114300A (ja) | 人工多能性幹細胞の製造方法 | |
Rapoport et al. | Glandular stem cells are a promising source for much more than β-cell replacement | |
JP2019118279A (ja) | 細胞凝集促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21903397 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022568288 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18265609 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021903397 Country of ref document: EP Effective date: 20230707 |